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Abstract 
The determination of cell membrane permeability and of the absorption and clearance 
rates is an important step in the pharmacokinetic profiling of a new drug candidate. In a 
similar way, research in cell biology relies on the development of cell penetrating biochem-
ical probes allowing to study and interfere with cellular functions and physiology. 
A variety of methods have been developed to estimate the ability of molecules to enter the 
intracellular space. They are based either on artificial membranes or on cellular models, 
with consequently different abilities to mimic the cellular permeation mechanisms. How-
ever, these techniques are often laborious, expensive and have to be combined to get a 
reliable characterization of the properties of the molecule of interest.   
This thesis introduces a new strategy to evaluate real-time absorption and clearance ki-
netics of different classes of molecules in living cells. The approach is based on the use of 
intracellular single-chain FRET-based biosensors with a versatile modular design. First, a 
proof-of-concept bioprobe for inhibitors of the enzyme human carbonic anhydrase II 
(HCAII) was developed and optimized for intracellular use: the cell-entry dynamics of a 
selection of well-known sulfonamide drugs was compared and monitored in real time. 
Then, we adapted the design of the sensory protein to generate a label-free biosensor for 
inhibitors of the p53-HDM2 interaction, a highly studied protein-protein interaction in 
cancer biology. The permeability and the kinetics of cell entry and washout of various 
underivatized small molecule and peptidic inhibitors could be measured. 
This thesis represents a step towards the introduction of a general approach for a low-
cost, rapid and minimally invasive evaluation of molecular permeabilities in the cell type 
of choice. Their modular design lends itself to be adapted to the detection of other families 
of molecules, provided that a binding protein for the molecule of interest is known. 
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Riassunto 
La determinazione della permeabilità, della velocità di assorbimento e di efflusso cellulari 
è una delle fasi più importanti nella valutazione delle proprietà farmacocinetiche di un 
nuovo candidato farmaco. Similmente, in biologia cellulare lo sviluppo di sensori bio-
chimici permeabili è essenziale per studiare ed interferire con le funzioni e la fisiologia delle 
cellule. 
Attualmente esistono una varietà di metodi per stimare la capacità delle molecule ad ac-
cedere lo spazio intracellulare. Tali metodi sono basati su membrane artificiali o modelli 
cellulari, e conseguentemente permettono di simulare i meccanismi di penetrazione cellu-
lare in modo più o meno appropriato. Ciononostante queste tecniche sono spesso labori-
ose, costose e necessitano di essere combinate per fornire una caratterizzazione complete 
della molecola di interesse. 
La presente tesi introduce una nuova strategia per valutare in tempo reale in cellule viventi 
il grado e la velocità di assorbimento ed efflusso di diverse classi di molecule. L'approccio 
si fonda sull'uso di biosensori proteici modulari e a catena unica basati sul fenomeno di 
FRET. In primo luogo, un sensore per inibitori dell'enzima anidrasi carbonica umana II 
(HCAII) è stato sviluppato ed ottimizzato per uso intracellulare: le dinamiche di penetra-
zione cellulare di note sulfonammidi hanno potuto essere comparate e monitorate in tempo 
reale. Successivamente, il design della proteina è stato modificato per generare un biosen-
sore codificabile geneticamente per il rilevamento di inibitori dell'interazione tra p53 e 
HDM2, oggetto di attenti studi in biologia del cancro. Il sensore ha permesso di misurare 
la permeabilità e le cinetiche di ingresso ed fuoriuscita cellulare di diversi piccole molecole 
e peptidi non-derivatizzati. 
I biosensori presentati in questo lavoro di tesi costituisce un progresso  nell'introduzione 
di un approccio generale per una valutazione low-cost, veloce e non-invasiva delle per-
meabilità molecolari sulla specie cellulare di interesse. Il design modulare si presta ad 
essere adattato al rilevamento di altre classi di molecole per le quali esiste una proteina 
legante. 
Parole chiave 
Permeabilità, biosensore, FRET, velocità di assorbimento cellulare, velocità di efflusso 
cellulare, HCAII, interazione tra p53 e HDM2. 
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 Introduction 
Cells membranes serve as biological selective barriers, permeable mainly to small, hydro-
phobic molecules. Over the years scientists from different disciplines (chemistry, biology, 
material science, physics and engineering) have developed various tools and techniques to 
circumvent this limitation, with the aim to observe and interfere with cellular processes. 
DNA1, siRNA2, 3, proteins4, 5, quantum dots6, radiotracers, magnetic resonance imaging 
contrast agents7 are just some examples of macromolecules that have been successfully 
delivered to the intracellular environment. Despite the richness of techniques and appli-
cations and the attention that they would deserve, the work presented here focuses on the 
cellular uptake of small molecules and peptides which represent by far the biggest families 
of molecules employed for therapeutic applications. 
1.1 Cellular uptake of molecules 
1.1.1 Relevance in drug development and background 
Of the thousands of novel molecules developed by drug discovery projects that bind to their 
therapeutic target, typically a few (1 out of 5000) become commercialized drugs8. The rea-
son of such a high failure rate is the presence of many physical and biochemical barriers 
between drug molecules and their targets: metabolic enzymes, cell membrane, efflux trans-
porters (e.g. P-glycoprotein, Pgp), unspecific binders, toxicity, the possible chemical insta-
bility and insolubility. All of these elements challenge the applications of a molecular spe-
cies in a living organism9.  
Figure 1:1 Schematic representation of in vivo barriers to drug delivery to the target. Adapted from Kerns et 
al.10. 
The effect of some of these barriers is predictable to some extent and can be controlled or 
even circumvented at the drug-design stage by structural modifications. In this context, 
the "Lipinski's rule of 5"11 is a useful collection of rules of thumb that identify five chemical 
properties that a compound has to fulfill in order to have good cell permeability. The rules 
state that good absorption or permeation of a molecule are more likely when: 
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? It has less than 5 H-bond donors (sum of all OHs and NHs) 
? Its molecular weight is below 500 
? Its logP is below 5 (or MlogP is above 4.15) 
? It has less than 10 H-bonds acceptors (sum of all Os and Ns) 
? Substrates of biological transporters are exception to the rule 
The rules have been established on the basis of empirical data and computational predic-
tions by Dr. Christopher A. Lipinski of Pfizer in 1997, and have since then a high impact 
on the drug development strategies and on the evaluation of drug candidates in pharma-
ceutical industries. 
Solubility and permeability of the compounds are so crucial that the U.S. Food and Drug 
Administration (FDA) created an ad hoc Biopharmaceutic Classification System (BCS), 
useful for defining criteria of similarity between approved and not-yet-approved molecules, 
with the aim of accelerating the review process and biowaivers attribution12. The BCS di-
vides the drugs into four classes based on their parameters of solubility and permeability 
both in vitro and in humans; the class boundaries are quantitatively defined and the meas-
urement methods are specified. Class I compounds are those showing high permeability 
and high solubility; these are the only compounds eligible for biowaivers. Class IV instead 
gathers the poorly soluble and poorly permeable compounds; these are high-risk com-
pounds that likely will not reach the market.    
It is important to underline that drug profiling is not an exact science: even though guide-
lines are available for the prediction and the improvement of Absorption (which directly 
correlates with solubility and permeability), Distribution, Metabolism, Excretion and Tox-
icity (ADMET) are very complex features that are subject to a high degree of uncertainty. 
Nevertheless, the pharmacokinetic (PK) profiling of drug candidates is fundamental in drug 
discovery programs because it alerts developers about potential issues and it allows early 
selection of lead compounds, therefore shortening the development process and increasing 
the chances of success13.    
1.1.2 Methods to assess drug permeability in vitro 
Although Lipinski's rules speak in favour of the presence of recurrent correlations between 
chemical structures and molecules' degree of permeability, they still remain non-exhaus-
tive14 qualitative observations. It is not trivial to derive in vivo quantitative data about mol-
ecules' permeability due to the complexity and the costs of studies in humans, too high for 
early drug discovery. As an alternative, several high-throughput scalable methods have 
been developed for measurements of in vitro permeability. The methods can be divided in 
two main classes, the non-cell-based and the cell-based, which differ in costs and degree 
of similarity to the tissues in living organisms.  
The non-cell-based techniques to assess permeability are essentially phospholipids-based 
techniques. Among the most important there are: 
i. Phospholipid Vescicle-based Permeability Assay (PVPA): the model consists in layers 
of small and large liposomes prepared by hydration in phosphate buffer and depos-
ited on a filter support by centrifugation15. The filter undergoes several freeze-thaw 
cycles which originate a compact barrier of layers of liposomes of different dimen-
sions that well mimic the heterogeneity of the intestinal epithelia. The filter is then 
loaded with a solution of the drug of interest (constituting the donor chamber) and 
placed on top of an acceptor chamber containing buffer. At different time points the 
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filter with the drug solution on the top are moved to a new acceptor chamber 
containing fresh buffer. At the end of the experiment the amount of drug found in 
the different acceptor chambers is calculated and plotted over incubation time.  
Figure 1:2 Scematic illustration of the PVPA barrier structure, where small and large liposomes are 
deposited on the membrane filter. Adapted from Gomes et al.16. 
ii. Immobilized Artificial Membrane-HPLC (IAM-HPCL): the technique is based on the 
use of a chromatographic column in which the stationary phase is made of silica 
covalently functionalized with phospholipids, like phosphatidylcholine (PC) which is 
the most commonly used. The affinity of the compound of interest for the lipid mon-
olayer correlates to its interaction with the cell membrane, and ultimately with its 
cellular permeability17, 18. Known internal standards are often used as reference for 
the calibration of the retention time. One of the major assets of the method consist 
in the fact that chromatographic systems are extremely common pieces of equip-
ment in research laboratories and allow rapid and automated measurements. 
iii. Parallel Artificial Membrane Permeability Assay (PAMPA): the method was developed 
by Manfred Kansy from Hoffmann-La Roche in 199819 and became quickly popular 
in both industrial and academic research laboratories. Similarly to the PVPA assay, 
acceptor and donor chambers are separated by a porous synthetic filter soaked with 
a solution of phospholipids in organic solvent (e.g. lecithin or PC in dodecane). Typ-
ically these separate reservoirs are created in 96-well plates, perfectly suited for 
High Throughput Screening (HTS). Differently from the PVPA assay, the lipids are 
not treated to form liposomes and in PAMPA the donor solution containing the com-
pound of interest is located below the membrane, which carries on top the acceptor 
acquous buffer.  
 
Figure 1:3 Schematic representation of the PAMPA experiment. Adapted from Kerns et al.20  
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After the desired period of incubation, the amount of compound present in both the 
donor and acceptor chamber is measured by LC/MS or UV absorbance; the perme-
ability through the membrane is then calculated with respect to the original con-
centration of the donor solution. Nowadays several variants of the method exist, 
where the lipid composition of the membrane is varied to improve the biomimetics 
of the model, to better simulate the membrane of specific tissues21 (e.g. the blood-
brain barrier, BBB) or to better fit the acid-base properties and lipophilicity of the 
drugs tested22. 
The non-cell-based methods offer the advantages of being simple, fast and cheap and 
therefore suitable for the screening of large families of molecules, essential in early drug 
discovery. They also provide versatility: the lipid composition employed in all these assays 
can be modified at choice according to the compound's properties23 and to the specificities 
of the tissue to mimic.  
Nevertheless, non-cell-based assays are valuable only for mimicking one single cellular 
permeation mechanism: passive diffusion. Other cellular access routes require either the 
consumption of energy (active transport) or the passage through paracellular junctions 
driven by gradients of concentration (passive transport, like diffusion). Active transport is 
carried out by endocytic proteins, membrane transport proteins and efflux pumps which 
are expressed and displayed on the surface of cells but cannot be integrated into artificial 
lipid-based membranes.  
 
Figure 1:4 Schematic representation of the major permeability mechanisms. Adapted from Kerns et al.24. 
Passive permeation has been historically considered as the most common route of drug 
absorption25. However, this belief was shown to be an oversimplification: the progress 
made in the field helped the discovery of membrane transport proteins for many active 
drugs. The scenario in a living organism is the one of highly diversified tissues, where 
expression levels of transporters, transporter's nature and drug concentrations at different 
biological membranes can vary26. In light of this complexity and despite their costs and 
slow handling, cell-based permeability assays are better simulators, crucial in the early 
development of therapeutics. Two most commonly used are described below: 
i. Madin Darby Canine Kidney (MDCK) cells: the use of this non-human cell line be-
came a helpful alternative to the more popular Caco-2 especially because of its faster 
growing rate and its robustness, which consequently allow a reduction of costs and 
effort for permeability testing. The formation of MDCK functional monolayers takes 
3-4 days of culture, and during this time the cells differentiate into columnar epi-
thelium, just like Caco-227 (vide infra). The cells are plated in devices that are very 
similar to those employed in PVPA assays: they settle and grow on a porous filter 
support which sperates donor and acceptor chamber. When the culture reaches 
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confluency and forms a tight layer, the test compound is added on its upper surface 
(apical side), where the cells develop microvilli, microscopic rod-shaped cell mem-
brane protrusions that increase the cell surface; the acceptor chamber is filled with 
just buffer, instead. At different time points aliquots from the two chambers are 
taken and the compound from each is quantified and plotted against incubation 
time. 
ii. Caco-2 cells: is the gold standard cell-line for in vitro permeability assay. Caco-2 
cells derive from a human colon carcinoma, have appreciable morphological simi-
larity to gastro-intestinal epithelial cells and, in contrast with MDCK cells, express 
a variety of cell membrane carrier proteins on their apical surface, therefore allowing 
the evaluation of the full spectrum of mechanisms of permeability. Caco-2 cells are 
plated and treated in the same way as MDCK cells, with the difference that they 
require 3 weeks of culture to express their maxim amount fo transporters and there-
fore to get ready to use28.  
Also the test conditions of cell-based systems are prone to some variations: the pH of the 
buffers in donor and acceptor solutions can be modified to better simulate specific biolog-
ical environments, buffer stirring systems can be employed to avoid undesired dishomo-
geneities and surfactants or organic solvents can be added to enhance drug solubility25.  
The comparison of results from multiple assays enriches the characterization of the drug 
of interest, allowing to discern in particular which permeability mechanism is predominant 
case by case.  
 
Figure 1:5 The comparison between Caco-2 and PAMPA assays provides insight on the permeability mecha-
nisms of a given molecule. Adapted from Kerns et al.20 . 
In fact, the stronger the correlation between results from non-cell-based and cell-based 
assays, the more dominant is passive diffusion. The more divergences are pronounced, the 
more active transport mechanisms become influential. 
1.1.3 Methods to achieve the cellular delivery of small molecules 
The intracellular access has been subject to extensive interdisciplinary studies in both 
academic research and pharmaceutical industries. If in academic research the primary 
aim is to gain a better understanding of cell biology by manipulating and observing with 
relatively small scale in vitro experiments, in pharmaceutical companies the aim is to 
change the cell biology of entire tissues in a living organism. Clearly, the approaches that 
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have been developed to achieve cellular delivery in the two fields are very different in terms 
of invasiveness and scale applicability. 
In academic research, several physical and mechanical methods that involve the temporary 
disruption of the plasma membrane have been developed. Among them the most important 
are: 
i. Microinjection: is performed by punching the cell membrane of single cells with cus-
tomized micropipettes, whose movement is controlled with a microscope. The tech-
nique has been employed to deliver a large variety of molecular entities: exogeneous 
proteins, DNA, siRNA, peptides, drugs and nanoparticles29. It is a laborious tech-
nique that requires a precision and care to target the cell of interest and piercing it 
without provoking cell perturbation. 
ii. Electroporation: is based on the application of high-intensity electrical impulses to 
the cell membrane. The impulses provoke a temporary strong polarization of the 
intracellular environment that induces in its turn the formation on the plasma 
membrane of pores 30, by which macromolecules can penetrate the cytoplasm. Du-
ration and intensity of the electric pulse determine the size of pores formed and 
therefore of the macromolecules that can penetrate the cell. 
iii. Sonication: relies on the use of ultrasounds, which induce strong vibrations of gas-
containing microbubbles (called ultrasound contrast agents, UCAs) in proximity of 
cell membranes. These vibrations promote the temporary deformation and opening 
of the membrane at multiple sites, allowing the influx of molecules31. 
iv. Particle bombardment: developed in 1987 for DNA transfer in plants32, this tech-
nique was soon adapted to the transfection of mammalian cells and tissues, and 
this is still nowadays the main application of the technique. Plasmid DNA is coated 
on the surface of tungsten or gold particles that are successively accelerated by the 
application of either a strong electric discharge or of a controlled gas pulse, typically 
helium. The particles in these conditions act as bullets and can penetrate the 
plasma membrane by collision, delivering the genetic material. The technique has 
been successfully used also for the introduction of dyes33, antigens34 and nanosen-
sors35 into cells. 
v. Cationic polymers (e.g. polyethylenimine, PEI) and liposomes: under the effect of 
hydrophilic/hydrophobic and coulombic interactions, cationic polymers and cati-
onic lipids form respectively aggregates and vescicles containing various molecules 
of interest. The positively charged external surface of these objects interacts with 
plasma membrane lipids and receptors, triggering their internalization mainly by 
endocytosis36. Currently they represent the most common non-viral gene delivery 
method, but they were also shown effective in the delivery of other molecular enti-
ties, like nanoparticles37. 
When instead of DNA, dyes and particles the object that has to be introduced into cells is 
a therapeutic molecule and the scale of the target system switches from a cell/tissue cul-
ture to humans, factors like toxicity, scalability, and localized delivery become crucial and 
none of the techniques listed above is suitable. Here is a non-exhaustive list of methods 
that are more compatible with therapeutic applications and that are currently protagonists 
of clinical trials: 
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i. Transferrin conjugation: transferrin (Tf) is an 80 kDa protein that works as iron 
transporter by chelating iron in the extracellular environment, binding to the trans-
ferrin receptors (TfR1, TfR2) on the cell membrane and getting internalized by en-
docytosis. The uptake of the complex Tf-TfR can be exploited to deliver different 
cargos in the cell: if chemically conjugated to Tf, anti-TfR antibody or their frag-
ments, toxins, DNA, nanoparticles and, more importantly, chemotherapeutic 
drugs38 are also internalized. Additionally, cancer cells have been proven to exten-
sively overexpress Tf receptors, and this makes the drug delivery even more tumor-
specific, lowers the toxicity and increases the therapeutic efficacy. 
ii. Toxins conjugation: toxins are peptides and proteins that have evolved in organisms 
as defensive systems to exert a detrimental effect on external biological targets. In 
the same manner as transferrin, toxins bind cell membrane receptors, are internal-
ized by endocytosis and can therefore be used as carriers to achieve localized deliv-
ery of therapeutic molecules to diseased tissues39. In order to limit the side effects 
induced by the administration of toxins, mutations or subunits selection can be 
applied, provided that they do not affect the interaction to the target membrane 
receptors. 
iii. Cell Penetrating Peptides (CPPs) and Antimicrobial Peptides (AMPs): are two families 
of short peptides of mainly cationic and hydrophobic residues (up to 30) known for 
their intrinsic ability to cross the cell membrane and eventually to carry a variety of 
different cargo objects together with them40. CPPs and AMPs share many character-
istics, but the latter are in particular studied for their antibiotic potential41. The 
discovery of CPPs and dates back to about 30 years ago, when a fragment of the 
trans-activator (TAT) protein of the HIV-1 virus was recognized to be responsible for 
its cellular uptake. Since then hundreds of various peptide sequences of either nat-
ural or synthetic origin or a combination of both (chimaeric peptides) have been 
discovered. Extensive studies have been run to reveal their mechanism of cell entry 
and to compile a list of peptides in order of internalization potency and endosomal 
escape ability. 
 
 
Figure 1:6 Schematic representation of the possible mechanisms of cellular entry of cell penetrating 
peptides. Adapted from Ramsey et al.40.  
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Comprehensively several mechanisms of entry can occur at the same time: they 
depend on the type of peptide, on its extracellular concentration, on the cell type 
tested and on the type of label/cargo they may carry along42. For these reasons cell 
entry routes result unpredictable, and require case by case investigations. 
iv. Structure modification: is the gold standard to improve the permeability of com-
pounds, it is the strategy that pharmaceutical companies explore since the begin-
ning of drug development programs. The chemical structure of the molecule is mod-
ified in such a way that its cellular transport is increased with the minimum detri-
ment to its function on the biological target. If this delicate task is achievable, then 
the compound can be employed without any need of derivatization, conjugation to 
carriers, special devices and additives, and this results in simplified ADME profiling 
procedures and reduced production costs. The identification of Structure-Property 
Relationships (SPRs) provides medicinal chemists with guidelines for adjusting the 
permeability of drug candidates by varying their chemical structure. Examples of 
modifications identified in this way are24:  
? replacement of ionizable, polar and H-donor/acceptor groups with isoelec-
tronic/isosteric atoms/functional groups; 
? reduction of size; 
? addition of apolar side-chains; 
? design of prodrugs (provisional inactive drug with improved permeability that 
gets metabolized in vivo to release the active moiety). 
1.2 FRET-based biosensors 
Cell biology still hides many secrets to the scientific community: the elucidation of 
cause/effect relationships in enzymatic cascades or metabolic events, the deciphering of 
physiological processes dynamics with spatial and temporal resolution are very topical 
needs in the field. In this context, biosensors, namely tools for the detection of cofactors 
or metabolites and for the sensing of protein-protein interactions, are essential. In partic-
ular biosensors based on the phenomenon of Fluorescence Resonance Energy Transfer 
(FRET) offer the advantage of being minimally invasive, genetically encodable in specific 
sub-cellular compartments and detectable with ordinary instrumentation. 
Fluorescence Resonance Energy Transfer (FRET) is a photophysical phenomenon which 
consists in the transfer of energy from a radiatively excited donor fluorophore to a second 
fluorophore that acts as acceptor. Some conditions have necessarily to be satisfied for 
FRET to occur:  
? The emission spectra of the donor fluorophore has to overlap with the excitation 
spectra of the acceptor: the wider the overlap, the higher the FRET yield; 
? Donor and acceptor fluorophores have to be in spatial proximity (approx. up to 10 
nm): the closer the fluorophores, the higher the FRET yield; 
? The dipole moment of donor and acceptor fluorophore have to be properly oriented 
relatively to each other: the closer the parallelism, the higher the FRET yield. 
The efficiency of the energy transfer is expressed by the following equation: 
? ? ??
?
?? ? ???
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where R represents the distance between the donor and acceptor fluorophores and R0, also 
called Föster radius, is a factor that characterizes each FRET couple in a defined environ-
ment: it depends on the spectral overlap between donor emission and acceptor excitation, 
on the quantum yield of the donor, on the refractive index of the medium and finally on 
the orientation of the transition dipoles of the fluorophores. 
FRET-based biosensors are very often composed of fluorescent protein (FP) pairs, which 
allow to bypass labeling steps and which can be fused ideally to any sensing motif of in-
terest. Independently from its nature (small molecule or protein), the object to detect has 
to trigger a relative movement of the two fluorescent proteins upon binding to the sensing 
motif: the relative movement in fact translates into a measurable reduction or increase of 
FRET efficiency. In the past decades various FRET-based biosensors that rely on different 
molecular mechanisms have been designed43. In the next section we will present the sen-
sors developed in our research group that are based on intramolecular conformational 
change. 
1.2.1 Semisynthetic FRET-based sensors, previous work 
In the recent past the Johnsson research group has developed a new category of biosen-
sors, the so called SNIFITs, acronym for SNAP-tag based Indicator proteins with a Fluo-
rescent Intramolecular Tether44. SNIFITs are semisynthetic biosensors because they are 
based on both a genetically encodable protein moiety and a chemically synthesized moiety.  
The protein moiety of the SNIFITs is a fusion of a binding protein (BP) for the analyte of 
interest, a FRET-donor and a self-labeling protein tag, like SNAP-tag45, 46. The FRET-donor 
can be either a fluorescent protein or a second self-labeling protein tag orthogonal to SNAP-
tag, like CLIP-tag47 that can be labeled with a fluorophore. SNAP and CLIP-tag derive from 
the human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT), a protein 
that can covalently bind to O6-benzylguanine derivatives with one of its cysteine residues. 
The two tags have been evolved to be specific to O6-benzylguanine (BG) or to benzylchloro-
pyrimidine (CP) in the case of SNAP-tag, and to O2-benzylcytosine (BC) derivatives in the 
case of CLIP-tag, and this allows the simultaneous labeling of the two proteins with differ-
ent substrates48, 49.  
 
Figure 1:7 Schematic representation of the specific and orthogonal labelling reactions of SNAP and CLIP fusion 
proteins respectively with BG and BC derivatives. Adapted from Gautier et al.47. 
The chemically synthesized moiety of the SNIFITs consists in a BG-derivative containing 
an acceptor fluorphore and a second ligand for BP. After labeling of SNAP-tag with the BG-
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substrate, this second ligand works as an internal binder that competes with the analyte 
of interest for the binding to the BP. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:8 Design and working principle of the SNIFITs based on the FRET between a fluorescent protein (FP) 
and a synthetic fluorophore introduced by SNAP-labelling (red star) (A) or on the FRET between two synthetic 
fluorophores introduced by orthogonal labelling of SNAP and CLIP-tag (red and green star respectively) (B). 
Adapted from Brun et al.44 
In absence of analyte (blue triangle in Figure 1:8) the sensor is in the closed conformation, 
where BP is bound to the internal binder, the donor fluorophore is in proximity of the 
acceptor fluorophore and the FRET efficiency therefore is high. When present, the analyte 
displaces the internal binder shifting the sensor to the open conformation, where the ac-
ceptor fluorphore can freely move around the bond to SNAP and the FRET efficiency is low. 
The quantification of the analyte in an unknown solution is enabled by the correlation 
between analyte concentration and ratio of the donor over acceptor fluorescence (FRET 
ratio). 
On the base of this design the following SNIFITs have been developed in the past:  
? a proof of concept sensor44 and a cell surface sensor50 based on the protein HCAII 
(very well known and far and wide characterized enzyme) for HCA-inhibitors (a va-
riety of them are commercially available); 
? a sensor for ?-aminobutyric acid (GABA) based on the GABAB receptor51; 
? a sensor for glutamate based on the ionotropic glutamate receptor 5 (iGluR5)52; 
? a sensor for acetylcholine based on acetylcholinesterase53; 
? a sensor for methotrexate based on E.Coli dihydrofolate reductase (eDHFR)54. 
SNIFITs offer some assets in comparison to other protein-based biosensors. First of all, the 
working mechanism is independent from the fact that, upon interaction with the analyte, 
the BP undergoes a significant conformational change: in fact the latter is often too small 
and this limits the dynamic range of the biosensor. Moreover, thanks to its modularity, the 
analyte concentration's range of response of a SNIFIT can be tuned simply by choosing 
appropriate internal binders, showing suitable affinity for the BP. Lastly, SNIFITs provide 
ratiometric responses, which are independent from the sensor concentration and therefore 
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advantageous for quantitative  applications55 in vitro but more importantly in cellulo, where 
the sensor concentration cannot be easily controlled. 
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 Aim of the project 
The rationalization of the factors that regulate the access to the intracellular compartment 
is an objective pursued by many researchers in different fields. In the world of biomedical 
research the determination of absorption and clearance rates of drug candidates in mam-
malian cells is a key step in the early understanding of their pharmacokinetic properties. 
Similarly, in academic research the development of cell penetrating probes is crucial for 
the investigation and the manipulation of cellular processes.  
The aim of this thesis is to provide a versatile and minimally invasive strategy to answer 
this need. The approach entails the use of genetically encodable FRET-based protein 
probes for in cellulo time-resolved molecular sensing. The correlation between the probes' 
responses and the cellular uptake/clearance of the compounds tested enables the identi-
fication of the determiners in molecular permeability.  
First, a proof of principle intracellular sensor based on the Human Carbonic Anhydrase II 
(HCAII) as binding protein was developed. This sensor was used as model to validate the 
protein geometry and the experimental setup and to test the feasibility of the approach. 
Second, driven by the aim of diversifying the applications of our strategy, we engineered 
an entirely genetically encoded biosensor for inhibitors of a protein-protein interaction (PPI) 
important in oncology, the one between the tumor suppressor p53 and its negative regu-
lator Human Double Minute 2 (HDM2)56. Small molecule and peptide inhibitors of the in-
teraction p53-HDM2 could be characterized and evaluated with respect to their potential 
to penetrate the cell membrane.  
As a long term perspective, the work presented in this thesis could be adapted to the de-
tection of other families of therapeutically relevant molecules and peptides, enabling their 
profiling and the rational-design of improved variants. 
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 HCA-based sensor for sulfona-
mides 
As briefly mentioned in Chapter 2, the starting point for the development of sensors for the 
assessment of the permeability of molecules was the conception of a sensor based on the 
protein HCAII, whose most important class of inhibitors are sulfonamides. The main rea-
sons of the choice are as follows: 
? a Snifit based on HCAII was already engineered and characterized in the Johnsson 
group and this provided a solid base of knowledge and a useful reference for com-
parison44; 
? HCAs have served as model proteins for studies in biophysics and medicinal chem-
istry and therefore their properties and structures have been described in great de-
tail57; 
? HCAs are clinically relevant enzymes and their inhibitors are widely used as thera-
peutics58; 
? HCAII, among the 16 isozymes existing in mammals, is one of the most character-
ized and the most catalytically efficient59 (i.e. diffusion controlled); 
? HCAII is a very stable cytoplasmic protein, easy to express and to purify in large 
amounts. 
This chapter contains an overview of the basics about the biological role of HCAs and of 
their inhibitors, a description of the sensor design and its working mechanism and, more 
importantly, the presentation of the performance of the sensor in the assessment of sul-
fonamides' permeability. 
3.1 Carbonic Anhydrases, an introduction 
Carbonic anhydrases (CAs) are enzymes present in both prokaryotic and eukaryotic or-
ganisms that contain a metal ion as an essential cofactor (Zn2+ in most cases) and catalyze 
the reversible hydratation of CO2:   
CO2 + H2O ? HCO3¯ + H+ 
As a consequence of their role as regulators of the interconversion between CO2 and bicar-
bonate, CAs are involved in many physiological processes like CO2 transport from tissues 
to lungs, pH homeostasis and several biosynthetic cascades (e.g. lipogenesis, ureagenesis 
and gluconeogenesis)60.  
In mammals, 16 different CA isozymes have been discovered, each with its specific func-
tion, tissue and subcellular localization. Their active site is at the bottom of a deep cavity, 
where a Zn2+ ion is coordinated by three histidine residues and a water-derived hydroxide 
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anion. In the hydrophobic pocket surrounding the metallic centre the enzyme accommo-
dates a CO2 molecule that undergoes nucleophilic attack by the hydroxide group present 
in the coordination sphere of Zn2+; bicarbonate is formed and it can leave the active site 
upon displacement by a water molecule, which is transformed to hydroxide by proton 
transfer and the catalytic cycle can restart.  
The mechanism of inhibition of CAs by sulfonamide derivatives (the biggest family of in-
hibitors and the only ones used in this work) is based on the substitution of the hydroxide 
in the coordination sphere of Zn2+ with the deprotonated nitrogen atom of the sulfonamide 
group61. Moreover, the interaction with sulfonamides is further stabilized by the formation 
of hydrogen bonds with the amino acids present in the vicinity of the active site62. 
 
Figure 3:1 Schematic representation of the Zn-bound HCAII active site in presence of CO2 (A), bicarbonate (B) 
and an arylsulfonamide inhibitor (C). Adapted from Krishnamurthy, et al.57  
Several sulfonamide-based HCA inhibitors are currently undergoing clinical trials while 
others are already widespread therapeutics used for the treatment of various diseases63. 
Some of the most important examples are acetazolamide, methazolamide and ethoxzola-
mide used mostly as antiglaucoma, antiepileptic drugs and as diuretics; topiramate and 
zonisamide, known as antiepileptic and antiobesity drugs; indisulam, studied for cancer 
treatment64; hydrochlorothiazide, for the treatment of osteoporosis and hypertension65. 
The diversity of the clinical applications is the proof of the involvement of CAs in numerous 
critical life processes and motivates the long lasting interest of the scientific community 
for these enzymes, still at the centre of many open questions. 
3.2 Sensor design 
Three HCA-based SNIFITs were developed in the Johnsson group before the project de-
scribed in this thesis was engaged: two were tested for sensing different HCA-inhibitors in 
vitro44 and one on the surface of mammalian cells50. The three sensors are based on the 
combination of a fusion protein, either SNAP-CLIP-HCA or SNAP-mCherry-HCA, with a 
SNAP-labelling substrate containing the fluorophore Cy5 and an aromatic sulfonamide as 
internal HCA ligand44. In the case of the CLIP-based fusion protein, a further labelling with 
a DY-547-containing CLIP-substrate is necessary for the formation of a FRET pair. Cy5 
acts as FRET acceptor while mCherry and DY-547 act as donors. These sensors allowed 
to reach FRET ratio changes (i.e. donor over acceptor fluorescence) up to 80% in in vitro 
measurements and up to 60% with the sensor on the cells surface. 
Despite the successful results of the approaches already developed, the need of a biosensor 
more suitable for intracellular sensing led former members of the group to explore new 
designs. They engineered a biosensor based on two fluorescent proteins (FPs) as FRET 
partners and whose functioning relies on the labelling of SNAP-tag with a non-fluorescent 
A B C
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substrate66. This strategy offers some important advantages: the elimination of the back-
ground fluorescence due to the labelling with synthetic dyes67; it increases the chances of 
the SNAP-substrate to be cellular permeable by reducing its size and hydrophilicity.  
3.2.1 The protein moiety 
The fusion protein of the sensor for sulfonamides contains SNAP-tag, HCAII as sensory 
protein and a fluorescent module. The new strategy is based on the integration of the FRET 
partners in the protein moiety, as FPs. In the specific case, eCFP and YPet were chosen for 
their suitability for FRET ratiometric experiments68: the two proteins show a good spectral 
overlap, photostability, short maturation times69 and an direct hydrophobic interaction 
which in the closed sensor increases the FRET efficiency and improves the dynamic range 
of the sensor70. In the construct eCFP and YPet are separated by a semi-rigid protein linker 
constituted by two Gly-Gly-Ser repetitions, that guarantee flexibility71, 72, inserted between 
two 15-residues-long poly-L-proline chains, that fold into a rigid helical structure73, 74. 
Such a linker is expected to keep the FPs apart in the open state of the sensor, without 
hampering the closure in the closed state, leading to an increased FRET ratio dynamic 
range. 
 
Figure 3:2 Design and working mechanism of the HCA-based sensor. 
3.2.2 SNAP-tag labelling molecules 
The synthetic molecules necessary to create the reversible connection between SNAP-tag 
and HCAII are composed of three main parts:  
? a SNAP-tag reactive moiety: as mentioned in Chapter1.2.1, both BG- and CP-deriv-
atives are substrates for the covalent labeling of SNAP-tag. Since there is no evi-
dence of generalizable differences between BG- and CP-containing compounds in 
terms of labeling kinetics and cellular permeability, both kinds of derivatives were 
synthesized; 
? a spacer: spacers of different lengths and polarities, containing polyethylene glycol 
units (EG5 or EG11) or alkyl chains (C6) or their combination (C6-EG2) were employed; 
? an HCAII ligand: as HCAII internal binder, a benzenesulfonamide terminal moiety 
was used. Meta- and para- derivatives were synthesized: they have different disso-
ciation constants for HCA (respectively high and low nM range57), and therefore they 
offer the possibility to choose the suitable opening/closing sensor kinetics and the 
range of analyte concentrations in which the sensor is responsive. 
Eight SNAP-substrates were synthesized and submitted characterization, in search for the 
best compromise between the needs of an appropriate length, of good solubility in aqueous 
FRET
emission excitation
YPet CFP
emission
excitation
18 
 
solution, of fast labeling kinetics and of high cellular permability. Detailed synthetic pro-
cedures and spectral data for the compounds are reported in Chapter 6.1. 
 
Figure 3:3  Final structure of the substrates for SNAP-tag labelling of the HCA-based sensor. 
3.3 Sensing sulfonamides in vitro 
The starting point of the study and of the optimization of sensor's features in vitro was the 
successful expression and purification of its protein moiety SNAP-YPet-Pro15(GGS)2Pro15-
CFP-HCA from HEK 293 cells by means of its C-terminal His-tag and the N-terminal Strep-
tag fusion. 1L of doxycycline-induced HEK 293 cell culture yielded 8.8 mg of pure sensor 
(cfr. Figure 3:4).  
 
 
 
 
 
 
 
Figure 3:4 SDS-PAGE of the HCA-based sensor protein purified from HEK 293 cells. 
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Subsequently, a qualitative evaluation of the properties of the synthetic SNAP-substrates 
presented in Chapter 3.2.2 was performed. In view of the application of the sensor for 
intracellular measurements, the substrates were first evaluated on the basis of their cel-
lular permeability and ability to react with SNAP-tag in cellulo. Then their activity towards 
SNAP-tag in the sensor construct was assessed. Finally, the best performers were charac-
terized with sulfonamides titrations in vitro, which led to select the substrates embodying 
the best compromise among all these factors. 
3.3.1 SNAP-tag labeling in cellulo with the substrates 
For the assessment of the substrates' ability to penetrate the cells and to react with a 
SNAP-tag containing fusion protein, a doxycycline-inducible U2OS semi-stable cell line 
expressing the protein SNAP-CLIP was established and treated as described in Chapter 
6.2.7. After overnight incubation with the SNAP-substrate to test, an excess of the fluores-
cent SNAP-substrate TMR-Star was added and the cells were incubated for further 30 min. 
The cells were subsequently lysed in presence of a fluorescent CLIP-substrate, BC-SiR, 
used as internal standard. The cells lysate was analysed by SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, cfr. Figure 3:5) and fluorescence scan: the in-
tensity in the TMR channel, inversely proportional to the achieved degree of labelling with 
the SNAP-substrate of interest, was normalized by the intensity in the SiR channel, making 
the quantification independent from the amount of sensor loaded on the gel. The labelling 
yield for the tested substrates was calculated by comparison of the corresponding fluores-
cence band to that of a positive (100% labelling) and of a negative (0% labelling) control, 
represented respectively by lysates of cells incubated with the non-fluorescent quencher 
SNAP-Cell Block and with just TMR-Star. 
 
Figure 3:5 Fluorescence scan of an SDS-PAGE of the lysates of SNAP-CLIP cell line incubated with the SNAP-
substrates. [a]: In the lysate of cells treated with SNAP-Cell Block there is no labelling with TMR-Star. The 
fluorescence detected in the TMR-channel is due to the bleed-through of the SiR signal; the labelling yield for 
the other substrates was adjusted taking into consideration this effect. 
The described experiment was performed only with mSA-containing substrates. The inter-
pretation of the results relies on the following assumptions: 
? the permeability of a SNAP-substrate is independent on whether the HCA internal 
binder is meta- or para-sulfonamide; 
? the efficiency of intracellular SNAP-labelling of the auxiliary construct SNAP-CLIP 
by a substrate is the same for both its meta- and para-sulfonamide isomers; 
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? the efficiency of intracellular SNAP-labelling is the same for both the auxiliary con-
struct SNAP-CLIP and the protein SNAP-YPet-Pro15(GGS)2Pro15-CFP-HCA. This is 
realistic since the crystal structure of SNAP-tag shows75 that its C-terminus (CLIP-
tag or YPet attachment site) is relatively far from the active site and points to a 
different direction, which reduces the probability for the protein fused at the C-
terminus to affect the labelling efficiency. 
The substrates 1a, 3a, 4a (respectively BG-C6-mSA, BG- and CP-C6-EG2-mSA) showed an 
almost quantitative intracellular labelling, which made them interesting candidates for the 
continuation of the project. On the contrary, compounds 2a and 2b (BG-EG5-, EG11-mSA) 
showed only partial labelling, which could be explained either by a poor cellular permea-
bility or by a low reactivity of SNAP-tag towards these substrates. For the purpose of an-
swering this question, they were included among the compounds further investigated. 
3.3.2 Sensor-labelling reactivity of the substrates in vitro 
The progression of the sensor-labelling reaction by each of the substrates was quantified 
over time: compounds 2a and 2b (BG-EG5-, EG11-mSA) were tested with the aim of clari-
fying the reason of the low labelling yield measured in cells, whereas for the other sub-
strates the goal was defining the proper labelling incubation time required for the in vitro 
use of the sensor.  
The details of the experimental protocol are described in Chapter 6.2.3. At different time 
points aliquots from a solution of protein SNAP-YPet-Pro15(GGS)2Pro15-CFP-HCA and sub-
strate of interest were taken and quenched by addition of a large excess of TMR-Star. 
Similarly to the procedure described in Chapter 3.3.1, the aliquots were analysed by SDS-
PAGE and fluorescence imaging. The intensity of the TMR fluorescence was quantified, 
compared to a negative control (0% labelling) and related to the degree of labeled protein. 
 
Figure 3:6 Sensor-labelling yields achieved by the substrates over time. 
The data summarized in Figure 3:6 shown that after two hours of incubation the labelling 
of SNAP-tag in the sensor construct was complete for all the substrates except for com-
pound 2a BG-EG5-mSA, which after the same time showed about 90% of labelling. Very 
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interestingly, these results proved that the in cellulo low reactivity of compounds 2a and 
2b (BG-EG5-, EG11-mSA) was likely due to their poor cellular permeability, rather than to 
a slow SNAP-labelling rate: in fact, while improving the solubility of the molecules, the 
ethylene glycol units increased their overall hydrophilicity, reducing their ability to cross 
the hydrophobic cell membrane. This effect was counterbalanced in compounds 3a, 3b 
(BG-C6-EG2-mSA, -pSA), 4a and 4b (CP-C6-EG2-mSA, -pSA) by a 6-alkyl chain; the shorter 
EG2 linker was yet sufficient for assuring good solubility in aqueous solutions. 
Two other noteworthy trends could be identified in the results: CP-derivatives were less 
reactive towards SNAP-tag than their BG-equivalents and mSA-derivatives were less reac-
tive than their pSA-equivalents. The first outcome confirmed what had already been found 
by former members of the group, who compared the labelling kinetics of CP- and BG-
carboxyrhodamine dyes76 and found that BG-derivatives show slightly faster labelling ki-
netics in vitro. As for the effect of the internal ligand, it could be rationalised by considering 
that since pSA-derivatives are stronger HCA-binders than the mSA-derivatives (cfr. Chap-
ter 3.2.2) the local concentration of the former around SNAP-tag in the sensor construct 
was higher than the local concentration of the latter. The reaction rate is directly propor-
tional to the concentration and this explains the difference in reactivity between isomers. 
Compounds 1a, 1b (BG-C6-mSA, -pSA), 3a and 3b (BG-C6-EG2-mSA, -pSA) proved to be 
the best performers in terms of both cellular permeability and of SNAP-reactivity; for this 
reason they were selected for the continuation of the project. 
3.3.3 In vitro titration of sulfonamide inhibitors  
The HCA-sensor labelled with each of the four selected substrates was tested for its ability 
to sense methazolamide, a commercially available HCA-inhibitor with a reported KD of 55 
nM77. As explained in Chapter 1.2.1, in absence of methazolamide the sensor was expected 
to stay in the closed conformation, where the close proximity of CFP to YPet would led to 
high FRET; in presence of methazolamide the intramolecular sulfonamide would be dis-
placed, the sensor would shift to the open conformation progressively with the increase of 
inhibitor concentration, while the energy transfer would decrease. Following the titration 
experiment, the ratio between donor emission (CFP) and acceptor emission (YPet) was plot-
ted against the increasing concentrations of methazolamide (cfr. Figure 3:7). 
 
 
 
 
 
 
Figure 3:7 Fluorescence titration curve of 
methazolamide with the HCA-based sen-
sor labelled with different substrates. 
Each plot shows the ratio donor (CFP) 
over acceptor (YPet) emission against the 
concentration of inhibitor. 0 1E-10 1E-9 1E-8 1E-7 1E-6 1E-5 1E-4 1E-3 1E-2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
 1a, BG-C6-mSA
 1b, BG-C6-pSA
 3a, BG-C6-EG2-mSA
 3b, BG-C6-EG2-pSA
C
FP
/Y
Pe
t
Methazolamide conc. (M)
22 
 
The conformational shift was clearly recognizable in the case of the sensor labelled with 
substrate 3b BG-C6-EG2-pSA, whereas it was just partially observed for the sensor labelled 
with 1b BG-C6-pSA and 3a BG-C6-EG2-mSA and not observed at all with 1a BG-C6-mSA. 
In the case of the last three substrates the high values of FRET ratio in absence of metha-
zolamide (last point on the left of the titration curve, cfr. Chapter 6.2.4) indicated that part 
of the sensor molecules were still in the open conformation. The factors that controlled 
this effect were likely to be the limited molecular length, the weakness of the mSA moiety 
as HCA-intramolecular binder or a combination of the two. In particular, the backbone 
BG-C6- forces the construct in a constrained geometry and makes the binding constant of 
the internal ligand thermodynamically achievable just in the case of the sensor labelled 
with the pSA-containing substrate 1b, which showed yet a fractional degree of closing in 
absence of inhibitor. As for substrate 3a, while the incorporation of EG2 in the molecule 
increased its length, the binding of the mSA moiety to HCA seemed to be still only moder-
ately favourable and the closing remained incomplete. 
In light of the performances of the different substrates in the test titration with methazo-
lamide, compound 3b was selected as the most suitable for the successive applications 
and it was therefore tested for the sensing of a selection of other HCA inhibitors (cfr. struc-
tures in Figure 3:8 (C)): ethoxzolamide, acetazolamide, benzenesulfonamide which are 
commercially available and a molecule made in house containing a pSA moiety, a C6 linker 
and a cysteic acid (compound 5). Compound 5 was synthesized as an example of supposed 
impermeable sulfonamide, due to the presence of a negative charge on the cysteic acid 
moiety at physiological pH: we hoped we could demonstrate the suitability of the biosensor 
to differentiate cell permeable and impermeable molecules. 
Figure 3:8 (A) Fluorescence titration curve of different inhibitors with the HCA-based sensor labelled with the 
substrate 3b BG-C6-EG2-pSA. Each plot shows the ratio donor (CFP) over acceptor (YPet) emission against the 
concentration of inhibitor; the data were fitted to a single-site binding isotherm (cfr. Chapter 6.2.4). (B) Fluo-
rescence emission spectra of the HCA-based sensor in presence of different concentrations of ethoxzolamide. 
(C) Chemical structures of the HCA inhibitors used. 
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Inhibitor ????(μM) ?????? (μM) ?? (nM) ???ref. (nM) 
Benzenesulfonamide 546 ± 33 229 ± 32 2100 ± 400 200-150057 
Acetazolamide 7.8 ± 0.1 3.8 ± 0.5 35 ± 6 2077 
Methazolamide 14.5 ± 0.2 6.1 ± 0.3 55 ± 4 5577 
5, pSA-C6-CyA 9.9 ± 0.8 4.1 ± 0.8 37 ± 10 n.d. 
Ethoxzolamide 0.16 ± 0.03 0.06 ± 0.02 0.5 ± 0.3 0.278, 477 
 
Table 3:1 In vitro ???, ???????? and ???of the inhibitors for the HCA-based sensor labelled with 3b. The reference 
?? are for HCAII. The values of ?? for each analyte was calculated using Equation 3:1 (see below). 
The sensor labelled with the substrate 3b BG-C6-EG2-pSA exhibited a maximum FRET-
ratio change of 189 ± 8 %. For each HCA inhibitor tested the titration curve is reported in 
Figure 3:9 (A). Different fittings of the intensity ratio data (cfr. Chapter 6.2.4) allowed the 
calculation of the ??? and of the ????????, which are the concentrations of inhibitor that lead 
respectively to 50% of the maximum FRET-ratio change and to 50% of the maximum 
change in either donor or acceptor channel. Noteworthy, the ??? value is not necessarily 
equal to the ????????79, as shown in Figure 3:9 for methazolamide.  
 
Figure 3:9 Fluorescence emission intensities of CFP and YPet and titration curve of the HCA-based sensor in 
presence of varying the concentration of methazolamide. The values of ??????  and ???????? for methazolamide are 
indicated by dashed lines. 
For a given analyte, the ???????? value is always higher than the absolute? ?? : it results in 
fact from the combination of the pure affinity of binding protein (BP) for the analyte and 
the ability of the latter to outcompete the intramolecular ligand. The relation between these 
quantities is expressed by the following equation: 
????
????????????????
? ??
??????????????
???????????
? 
in which the effective molarity ???? corresponds to the concentration of the free intramo-
lecular ligand necessary to open half of the sensor molecules if the sensor would be labelled 
with the very same intramolecular ligand, ???????????????? is the dissociation constant of the 
free intramolecular ligand for the BP, ????????? ?????? is the dissociation constant of the ana-
lyte for the sensor, ???????????? is the dissociation constant of the analyte for the BP. ???? is 
a parameter that characterizes a sensor labelled with a given substrate and is equivalent 
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to the ????????? ?????? when the analyte is the substrate itself. In the case of the HCA-based 
sensor labelled with 3b BG-C6-EG2-pSA, it was impossible to measure directly by titration 
the ???????? of 3b because of its limited solubility. Nevertheless, knowing that the ?? of pSA-
derivatives similar to 3b is approximatively 100 nM57 and considering the results for one 
of the HCA inhibitors of Table 3:1 (e.g. methazolamide), the ???? of the sensor could be 
estimated: 
? ??? ? ?
????????????????
???????????
? ???????????????? ? ?
???????
????? ? ?????? ? ?????? 
Equation 3:1 Calculation of the effective molarity ???? of the HCA-based sensor. 
The ??????????? listed in Table 3:1 were calculated on the basis of this value of ???? and they 
are in close agreement with those found in literature. Noteworthy, the value of ???? found 
is lower than those previously published44 by former members of the Johnsson group for 
other sensors. The opening is termodinamically more favourable for the sensor with the 
new design with respect to the HCA-based SNIFITs. In these latter constructs just one 
fluorescent protein44 or CLIP-tag50 were inserted between SNAP-tag and HCA, whereas our 
biosensor carries two fluorescent proteins: this likely increases the constraints in the ge-
ometry of the new construct.  
3.3.4 In vitro opening kinetics of the sensor in presence of sulfonamide 
inhibitors 
In the prospect of investigating the uptake rate of HCA inhibitors in living cells, the sensor's 
opening kinetics were measured at 37°C in vitro in the first place. The inhibitors were 
added to the sensor labelled with compound 3b at the highest concentrations employed in 
titration experiments, in order to trigger the fastest opening of the sensor molecules; the 
FRET-ratio was plotted against time and fitted with a single exponential function. 
 
Table 3:2 In vitro opening half-lives at 37°C of the 
HCA- based sensor labelled with 3b in presence 
of saturating concentrations of inhibitors.  
 
Figure 3:10 Example of opening kinetics in vitro of the HCA-based sensor labelled with 3b in presence of 
methazolamide 300 μM or HEPES buffer. 
As previously demonstrated for the sensors developed in the Johnsson group50 (based on 
interaction and displacement of an intramolecular tether, cfr. Chapters 1.2.1 and 3.2), the 
kinetics of opening is mainly governed by the rate of unbinding (koff) of the intramolecular 
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ligand, which can eventually be interchanged to tune the sensor's kinetics at will. However, 
due to the reasons presented in the previous paragraphs, the HCA-based sensor described 
in this thesis was fully functional only upon labelling with the pSA-containing compound 
3b (cfr. Figure 3:7). In these conditions, the average opening half-life measured with the 
tested inhibitors was t1/2,open = 77 ± 8 s, which corresponds to a koff = (9 ± 1)·10-3 s-1 of the 
pSA-containing intramolecular ligand. This value was globally slower than the one reported 
for similar pSA-derivatives57 (koff ~ 30·10-3 s-1) but very similar to the one previously meas-
ured on cells surfaces with the HCA-based SNIFIT also labelled with a pSA-containing 
substrate50 (koff ~ 10·10-3 s-1).  
3.4 Sensing sulfonamides in cellulo 
After having elucidated some of its key properties in vitro, the ability of the sensor to allow 
direct, non-invasive intracellular detection of HCA inhibitors was tested. The protein moi-
ety of the sensor was expressed in a doxycycline-inducible U2OS cell line and it was found 
having a uniform, mainly cytosolic distribution (cfr. Figure 3:11). 
 
Figure 3:11 Example of microscopy images of the U2OS cell line expressing the HCA-based sensor and labelled 
with the compound 3b. After CFP excitation, the CFP emission image (A) and the YPet emission image (B) were 
registered. 
The labelling was performed by over-night incubation with the dye-free substrate 3b. 
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3.4.1 In cellulo titration of sulfonamide inhibitors 
The intracellular concentration-dependent response of the sensor to HCA inhibitors was 
evaluated by fluorescence microscopy on the labelled cell line in titration experiments. 
 
Figure 3:12 In cellulo fluorescence titration curve of different inhibitors with the HCA-based sensor labelled 
with the substrate 3b BG-C6-EG2-pSA. 
 
 
 
 
 
 
Table 3:3 Comparison between in cellulo and in vitro C50s of the HCA-inhibitors for the sensor labelled with 3b. 
With the only exception of compound 5 pSA-C6-CyA, the C50s of the inhibitors measured 
in vitro and in cellulo were very similar (cfr. Table 3:3), which suggested that the sensor 
retained its properties when expressed in mammalian cells and that the inhibitors entered 
the cells by passive diffusion. In fact, the presence of active efflux or influx pumps would 
have altered the titration profile of a compound by shifting its C50 respectively to higher or 
lower concentrations. The case of compound 5 was separate: while in vitro it displayed a 
good affinity for the HCA-sensor (comparable to the one of acetazolamide and methazola-
mide), it turned out to be totally ineffective in cellulo, where it did not trigger any FRET 
ratio change (cfr. Figure 3:12). Considering that it contains a sulfonic acid moiety which is 
negatively charged at physiological pH (pKa=1.3)80, the molecule is very likely impermeable 
to the cell membrane. Thus compound 5 represented a good control, since it allowed to 
demonstrate that differences in molecular premeability of sulfonamides could indeed be 
detected with the help of the developed biosensor. 
The passage from the in vitro to the in cellulo sensor's use provoqued however a loss of 
FRET-ratio dynamic range of more than 60%, from about 190% to about 70% (cfr. open 
and close FRET-ratio values in Figure 3:8 and Figure 3:12). This might be due to the fact 
Inhibitor C50 in cellulo (μM) 
C50 in vitro 
(μM) 
Benzenesulfonamide (4 ± 2)·102 (5.5 ± 0.3)·102 
Acetazolamide 8 ± 4 7.8 ± 0.1 
Methazolamide 14 ± 5 14.5 ± 0.2 
5, pSA-C6-CyA n.d. 9.9 ± 0.8 
Ethoxzolamide 0.07 ± 0.02 0.16 ± 0.03 
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that the cellular space is densely occupied by biomacromolecules, like proteins, nucleic 
acids, sugars and organelles81; these objects are responsible for a background autofluo-
rescence which can alterate the absolute results of the measurement by reducing the sig-
nal-to-noise ratio (SNR)82, 83. Moreover, the macromolecules can interact with the sensor 
and therefore have an often unpredictable and unclear effect on its response. Despite these 
limitations, the HCA-based sensor exhibited a dynamic range sufficiently wide to allow 
reliable measurents of intracellular concentrations of sulfonamides. 
3.4.2 In cellulo kinetic characterization of the sensor in presence of sul-
fonamide inhibitors 
The evaluation of the in cellulo kinetic response of the HCA-based sensor was performed 
with batch experiments in 96-well plates on the labelled cell line. The cells were imaged 
over time by fluorescence microscopy following the addition of the analyte of interest; after 
attainment of equilibrium, the supernatant solution containing the analyte was exchanged 
with fresh buffer and the microscopy imaging over time was restarted.  
Ideally, the application of the biosensor to time-resolved intracellular concentration meas-
urements requires opening and closing rates faster than the rate of the analyte's intracel-
lular concentration change. This condition becomes particularly stringent when the ana-
lyte to sense can pass very rapidly through the cell membrane: in this case the opening 
and closing rates (which depend on the koff respectively of the tether ligand and of the 
analyte) can represent the bottleneck of the measurement and prevent the recognition of 
differences in cell entry and exit kinetics between species. 
The studies conducted in vitro revealed that the fully functional version of the HCA-based 
sensor (labelled with the pSA-containing substrate 3b) is characterized by a relatively slow 
opening rate, determined by the koff of the intramolecular tether. Indeed, the experiments 
in cellulo showed that the opening half-life of the sensor was very similar for all the inhib-
itors tested with the exception of the sulfonic acid-derivative 5, which proved to be imper-
meable (cfr. Figure 3:13 (A)). 
 
Figure 3:13 (A) Opening kinetics measured by live cell imaging of the intracellular HCA-based sensor labelled 
with 3b in presence of acetazolamide 300 μM, methazolamide 300 μM, compound 5 or HBSS buffer. (B) Closing 
kinetics after removal of the inhibitors and after incubation with fresh HBSS buffer. 
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Table 3:4 Opening half-lives measured in cellulo and in vitro of the HCA-based sensor labelled with 3b in 
presence of saturating concentrations of inhibitors. 
For all the cell permeable inhibitors the opening half-life values in cellulo were comparable 
to the one attained in vitro: this proved that benzenesulfonamide, acetazolamide, metha-
zolamide and ethoxzolamide are all characterized by high cellular permeability and that 
their cell entry rates exceed the biosensor's opening rate, preventing the differentiation of 
their permeabilities.  
The clearance rates of the inhibitors from the cells were also evaluated. The solutions con-
taining the inhibitors were manually removed and fresh HBSS buffer was added to the 
cells right before the restarting of the time course imaging (dead time of about 30 s). This 
technique presented two main drawbacks: it only allowed to dilute the inhibitor, instead 
of removing it completely with continuous buffer exchange; also, the addition of fresh 
buffer to the cells provoqued systematically an artificial upshift of the FRET ratios of about 
0.05 units with respect to the plateau attained at the end of the internalization. For these 
reasons these experiments were accounted just for the qualitative information provided. 
For all the inhibitors (but compound 5) the plateau of FRET ratio achieved after incubation 
with the HBSS buffer was higher than the FRET ratio value of control cells, treated just 
with buffer (cfr. Figure 3:13 (B)). Small differences with respect to the control can be jus-
tified by the fact that, despite the important dilution, the inhibitors were not completely 
eliminated from the batch setup and therefore they could still be partially in the cells. 
However, the case of acetazolamide was different: the FRET-ratio decrease over time upon 
incubation with fresh buffer in fact was minimal and it seemed to stabilize at a much 
higher value than the one of the control, as if the molecule was retained in the cells. Acet-
azolamide and methazolamide, which have very similar chemical structures, have been 
found to unbind HCAII with very similar kinetics84, which made the difference detected in 
the washout experiment even more surprising. This outcome could explain the disagree-
ment between the cell entry kinetics of acetazolamide measured with the biosensor and 
the results of another study85, reporting that the permeability of acetazolamide measured 
with the Caco-2 cells model is poor, more than 10 times lower than the reference com-
pound carbamazepine. In fact, the experiments on the cellular monolayer do not allow to 
distinguish the two steps of the process of transport through cells, entry and escape; on 
the contrary, the biosensor revealed that, after a quick penetration, acetazolamide is held 
in the cell, and for this reason it might not reach the acceptor chamber of the Caco-2 cells 
reservoir. 
Acetazolamide and methazolamide displayed very different clearance profiles with the sen-
sor, although they have very similar polar surface areas (115 and 105 Ä2, respectively86, 87) 
Inhibitor ????????? (s)  in cellulo 
????????? (s)  
in vitro 
Benzenesulfonamide  
(7 mM) 74 ± 12 68 ± 1 
Acetazolamide  
(300 μM) 113 ± 25 83 ± 1 
Methazolamide  
(300 μM) 88 ± 21 75 ± 1 
5, pSA-C6-CyA  
(600 μM) n.d. 73 ± 1 
Ethoxzolamide  
(20 μM) 89 ± 21 88 ± 1 
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and they both seem to enter the cells by passive diffusion66. Based on the information 
available on the DrugBank database reporting that the degree of plasma protein binding 
is 98% for acetazolamide86 against 55% for methazolamide87, it was proposed that the rea-
son for the different behavior of the two molecules lied in the different degree of binding to 
albumin, which represents around 19% of the cytosolic and 60% of the plasma protein 
content88, 89. However, for this hypothesis to be realistic, the C50 of acetazolamide obtained 
in vitro (where the BSA concentration was 0.5 mg/ml) should have been significantly lower 
than the one obtained in cellulo (where the BSA concentration is about 40 mg/ml); since it 
was not the case, the issue was left without answer.  
3.4.3 Conclusions and outlook 
The present chapter focuses on the engineering and testing of a novel FRET-based biosen-
sor for inhibitors of the enzyme Human Carbonic Anydrase II (HCAII). Its design, based on 
the use of fluorescent proteins as FRET-partners, constitutes an innovation with respect 
to the previously developed sensory proteins SNIFITs, inasmuch as it does not require 
labelling with synthetic fluorophores and it is therefore more suitable for intracellular ap-
plications.  
Initially, a selection of SNAP-tag non-fluorescent substrates was successfully synthesized 
and evaluated with respect to the ability to penetrate the cell membrane and to convert 
rapidly the sensor into a functional state. Following the identification of the best-perform-
ing substrate, the labelled sensor was used to sense multiple sulfonamides in vitro, where 
it displayed a large FRET-ratio change of about 190%, a high signal-to-noise ratio and a 
good correlation between the affinities measured and those reported in literature. Then the 
biosensor was expressed, assembled and tested in living cells, where its suitability for 
quantifying and comparing real-time absorption and clearance kinetics of various sulfon-
amides was proved. In particular, it was found that the pSA and sulfonic acid-containing 
compound 5 was cell impermeable, whereas all the other tested inhibitors required less 
than 5 minutes to saturate the intracellular bioprobe. Also, the sensor revealed remarkable 
differences in the washout kinetics of two very similar approved drugs, acetazolamide and 
methazolamide: they were both taken up by the cells fairly quickly, but while methazola-
mide could be also rapidly removed from the cytosol, acetazolamide had extremely long 
clearance times. These findings highlighted the limitations of permeability studies based 
on the Caco-2 cells model, classifying acetazolamide as poorly permeable and unable to 
provide detailed information on the two separate processes of cellular absorption and 
washout. 
The described biosensor provides the opportunity to investigate the cell permeabilities of 
multiple sulfonamide drugs or sulfonamide-derivatives, while comparing their absorption 
and clearance kinetics in a single experiment on the same living cells of choice. Further 
work on the project would focus on the search of an HCA-internal ligand with an affinity 
strong enough to guarantee the achievement of the sensor's close conformation, but able 
to provide at the same time faster opening kinetics, which would increase the temporal-
resolution of the bioprobe. Also, more tests would be performed to elucidate the reasons of 
the cytosolic retention of acetazolamide, which unfortunately are still unclear. Finally, the 
approach and the sensor's design presented in this chapter can be potentially adapted to 
study the permeability of many other classes of molecules, provided that a binding protein 
for the molecule is known and that a suitable intramolecular ligand can be synthesized. 
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 Label-free p53-based sensor 
for inhibitors of the p53-HDM2 interac-
tion 
The successful development of an intracellular sensor for HCA inhibitors and its efficient 
use to assess the permeability of sulfonamides encouraged us to adapt the bioprobe design 
to sense disruptors of a protein-protein interaction (PPI) highly studied in cancer biology, 
the one between the transcription factor p53 and its negative regulator HDM2.  
This chapter starts with essentials of the biological relevance of PPIs in general, and more 
precisely of the role and the features of the p53-HDM2 interaction; the distinctive charac-
teristics of their small molecule and peptide inhibitors are also presented. Then, the design 
of the label-free biosensor and its performance under physiological and non-physiological 
conditions are described. 
4.1 Introduction  
4.1.1 Protein-protein interactions as therapeutic targets 
The development of high-throughput technologies and decades of research in proteomics, 
genomics and network biology have revealed the importance of protein-protein interactions 
in the control of critical cellular processes like gene regulation90, signaling cascades, me-
tabolism and control of the cell cycle91. Because of their implication in key physiological 
functions, defective PPIs have been linked to a large number of diseases92, 93 and represent 
highly investigated therapeutic targets. The development of PPIs' inhibitors is yet a big 
challenge94: while the ligand binding pockets of enzymes are usually deep and well-framed, 
the contact surface of protein-protein interfaces is often wide, flat and hydrophobic, which 
badly matches with drugs bioavailability determinants like solubility and low molecular 
weight. However, alanine-scanning mutagenesis studies revealed that frequently most of 
the protein-protein binding energy depends on localized regions of few key residues, called 
"hot spots"95, whose identification facilitates targeted modulators' development and there-
fore enables PPIs druggability.  
PPI inhibitors can be divided into three categories, depending on the degree of complexity 
of the surface where the hot spots are located96:  
i. small, linear epitopes can be targeted by small molecules and short peptides;  
ii. secondary-structural epitopes (which are often groove-shaped) require small mole-
cules and peptides able to organize in 3D-structures, e.g. ?-helixes, ?-sheets or 
mimics;  
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iii. tertiary-structural epitopes are shallow and dynamic and therefore require inhibi-
tors able to undergo or trigger structural rearrangements. 
An interesting example from the second category are peptides constrained in an ?-helical 
conformation which seems to be well suited to mimic the topology of a large portion of PPI's 
interfaces97. 
 
Figure 4:1 Schematic representation of covalent linkages to lock ?-helixes in peptides. Adapted from Jamieson 
et al.98. 
The geometrical constraints can be created through a variety of covalent chemical bonds, 
such as triazole99, disulfide100, lactam101 and hydrocarbon bridges (cfr. Figure 4:1). The 
peptides locked via this latter kind of connection are called "stapled peptides": they are 
synthesized102 by ruthenium-catalysed olefin metathesis between the side chains of resi-
dues i and i+4 or i and i+7, which originate respectively 8- and 11-carbon tethers respon-
sible for the stabilization of helices of one or two turns. Stapled peptides stand out from 
the variety of therapeutic peptides for some key caracteristics103:  
? their excellent pharmaceutical stability, due to the fact that the alkyl linkage pro-
tects the peptides from proteolysis;  
? their improved affinities with respect to the corresponding native sequences, due to 
formation of additional hydrophobic interactions between the hydrocarbon staple 
and the surface of the target protein98;  
? their good cellular penetration, promoted both by the increased hydrophobicity of 
the overall structure and by their interaction with the cell membrane proteins and 
sugars104.  
The success encountered by this class of peptides in clinical trials105 encourages research-
ers to explore their therapeutic potential in many diseases-related PPIs. 
4.1.2 p53 and HDM2  
p53 is a nuclear transcription factor that controls, among other functions106, cellular apop-
tosis and growth arrest in response to DNA damage and to a variety of stress signals107. 
Since its activation prevents the propagation of cells containing potentially oncogenic DNA 
mutations, it is considered to function as a tumor suppressor protein, and loss of function 
mutations in the p53 gene have been discovered to promote the development of over half 
of human cancers108 (cfr. Figure 4:2).  
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Figure 4:2 Frequency of mutations, deletions and combination of alterations in the genes of p53 and MDM2 in 
cancers. Adapted from Burgess et al.109 
In healthy cells, the cellular concentration of p53 is very low and tightly regulated by the 
presence of several antagonists110. HDM2 is the most important of them, and its expression 
levels are controlled by p53 itself, which forms an auto-regulated negative feedback loop111. 
HDM2 exerts the function of an oncogene, mostly in a p53-dependent manner (but not 
only112): high HDM2 levels reduce p53 concentrations and therefore are associated with 
increased cancer risk. The negative regulation of p53 by HDM2 relies mainly on the follow-
ing mechanisms112:  
? ubitiquination: HDM2 serves as an E3 ubiquitin protein ligase that targets p53 for 
proteasomal degradation;  
? nuclear export: HDM2 promotes the translocation of p53 from the nucleus, where 
it is functional, to the cytoplasm, where it gets degraded113; 
? occupation of the transactivation domain: the HDM2-binding site of p53 coincides 
with its N-terminal ?-helical domain that is also responsible for its transcriptional 
activity;  
? block of p53-translational activators: HDM2 is responsible for the ubiquitination of 
the ribosomal protein L26, known as a p53-translational activator114. 
The surface of contact between p53 and HMD2 is notably hydrophobic and small: just a 
limited number of amino acids have been identified as hot-spots, and they are located on 
the N-terminal domain for both the partners. In particular, three amino acids on p53 
(Phe19, Trp23 and Leu26) have been identified as crucial for the interaction to take place: 
they all belong to the portion of the transcription factor that has been resolved by crystal-
lization in complex with HDM2 (p5315-29) and that is know to adopt an ?-helical confor-
mation upon binding115 (cfr. Figure 4:3). Only HDM2 has a structurally defined binding 
site, and for this reason the vast majority of inhibitors of the p53-HDM2 PPI is represented 
by molecules that bind to HDM2.  
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Figure 4:3 Crystal structure of HDM217-125 (grey) in complex with p5315-29 (red). The C-terminus of the p5315-
29-peptide is shown in green and the N-terminus of HDM217-125 is shown in blue. The side chains of the triad 
of p53 amino acids crucial for the interaction with HDM2 are coloured in yellow (PDB: 1YCR115). 
Both p53-derived peptides and small molecules with hydrophobic groups able to mimic 
the triad of p53's hot spots have been successfully developed as disruptors of the interac-
tion p53-HDM2. Examples of inhibitors are: nutlins, family of cis-imidazolines developed 
by Roche and displaying KDs between 0.09 and 14 μM116 and currently involved in clinical 
trials109; the small molecule RG7112 discovered by a team of researchers in Hoffmann-La 
Roche117, 118 and having an IC50 of 18 nM; ATSP-7041 developed by Aileron Therapeutics119 
and PMI120, two cell permeable ?-helical staple peptides with binding constants respec-
tively of 0.9 and 3 nM.  
4.2 Sensor design 
The p53-based sensor follows the model of the HCA-based sensor, differing just in that 
SNAP-tag is substituted by a portion of p53 and that HCA is replaced by HDM2. As p53 
wild-type peptide, the fragment containing residues 15-29 was chosen, since this portion 
was shown to be the HDM2-interaction partner by crystallography (cfr. Figure 4:3) and 
since its binding constant (KD = 575 nM121) seemed to be at the same time suitably strong 
to close the sensor in the absence of inhibitors and weak enough to allow the sensor's 
opening in presence of  inhibitors in the nM-μM range. As for HDM2, after having encoun-
tered some difficulties in the expression and purification of the sencor containing the full 
protein, the sensor was constructed using uniquely the portion 1-125, proven to be nec-
essary and sufficient for p53-binding115, 122. Moreover, since the crystal structure of the 
complex shows that the C-terminus of the p5315-29-peptide and the N-terminus of HDM2 
are pointing to the same direction (cfr. Figure 4:3, green and blue termini), the two inter-
acting partners were placed respectively at the N-terminus and at the C-terminus of the 
fusion protein, in order to preserve the good relative orientation (cfr. Figure 4:4). 
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Figure 4:4 Design and working mechanism of the p53-based sensor. 
The binding partners being in this case portions of two proteins, the sensor was entirely 
genetically encodable and no labelling was required to make it functional. This feature 
made it particularly attractive for intracellular application, since the experiments could be 
performed without any preliminary cell treatment and with minimal perturbation of the 
cells. 
4.3 Sensing inhibitors of the interaction p53-HDM2 in vitro 
4.3.1 In vitro titration of inhibitors of the p53-HDM2 interaction 
The sensor was successfully expressed in HEK 293 cells and isolated by affinity purifica-
tion thanks to its C-terminal His-tag and N-terminal Strep-tag: 1L of doxycycline-induced 
HEK 293 cell culture yielded 3.7 mg of pure sensor (cfr.Figure 4:5). 
 
 
 
 
 
 
 
 
 
 
Figure 4:5 SDS-PAGE of the p53-based sensor protein purified from HEK 293 cells. 
 
The ability of the protein to sense both small molecules and peptides inhibitors of the p53-
HDM2 interaction was evaluated in vitro. 
The inhibitors employed in the test (see sequences and structures in Table 4:1 and Figure 
4:6) are:  
? three small molecules, namely Nutlin 3a and two other imidazole-derivatives (1CFY 
and 5CGU);  
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? the stapled peptide sMTide CIS, derived from the sequence of the above-mentioned 
PMI peptide and isomer of the previously published strong peptide inhibitor called 
sMTide-02A123; 
? the D-peptide, phenylalanine-fluorinated analogue of the PMI-based proteolysis-re-
sistant DPMI? peptide124.   
With the exception of Nultin 3a which is commercially available, all the inhibitors were 
provided by the industrial partner Dr. T. Vorherr (Director Peptide Discovery, Novartis In-
stitute of BioMedical Research). 
 
 
 
 
Table 4:1 Sequences of the p5315-29-peptide and of the peptide inhibitors employed in the experiments. The i, 
i+7 isomeric stapling sites in sMTide CIS are indicated with XR and XS. D-amino acids are indicated in lowercase 
letters. W6-Cl is a tryptophan derivatized with a Cl on carbon-6, fCF3 is a para-trifluoromethyl derivatized D-
phenylalanine. 
 
Figure 4:6 Chemical structures of the inhibitors of the interaction p53-HDM2 employed in the experiments. 
As explained in Chapter 1.2.1 and 3.3.3 for the HCA-based sensor, in absence of inhibitors 
the sensor was expected to maintain a closed conformation, characterized by the proximity 
between CFP and YPet which leads to high FRET; on the other hand, the presence of in-
creasing concentration of inhibitor displaces progressively the intramolecular ligand, shifts 
1CFY 5CGU Nutlin 3a
sMTide CIS
D-peptide
Peptide Sequence  
p5315-29 NH2-SQETFSDLWKLLPEN-COOH 
sMTide CIS Ac-TSFXREYW6-ClALLXS-NH2 
D-peptide NH2-dwwplafCF3eallr-NH2 
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the sensor to the open conformation and provokes therefore a decrease of FRET. This grad-
ual effect is clearly visible in the emission spectra of the sensor on varying the sMTide CIS 
concentration (cfr. Figure 4:7 (B)). 
 
 
Figure 4:7 (A) Fluorescence titration curve of different inhibitors with the p53-based sensor. Each plot shows 
the ratio donor (CFP) over acceptor (YPet) emission against the concentration of inhibitor; the data were fitted 
to a single-site binding isotherm or to a Hill's equation (cfr. Chapter 6.2.4). (B) Fluorescence emission spectra 
of the p53-based sensor in presence of different concentrations of sMTide CIS.  
 
Table 4:2 In vitro ???, ???????? and ?? of the analytes for the p53-based sensor. The reference ?? were either 
published for analogues of the peptide used or calculated by the coworkers at Novartis by TR-FRET assay 
(displacement of N-terminally Cy5- labelled p53(18-26)). The solubility limits were calculated: [a] by the cowork-
ers at Novartis125, at pH=6.8; [b] in our laboratory by light absorbance at 280 nm, at pH=7.2. 
As noticeable in Figure 4:7 (A), for 5CGU, Nutlin 3a and D-peptide the titration curves 
could not be completed at high concentrations because of their limited solubility in aque-
ous solution. This prevented a precise calculation of the sensor binding parameters (in 
particular for Nutlin 3a and D-peptide, cfr. Table 4:2); yet these values could be estimated. 
Noteworthy, the titration curves of 1CFY and sMTide CIS required a fittitting with binding 
isotherms characterized by an Hill's coefficient equal to 2 (cfr. Chapter 6.2.4), which might 
indicate the presence of two binding sites on HDM2 for these compounds; however, this 
hypothesis was not further investigated. 
The p53-based sensor displayed an average maximum FRET-ratio change of 170 ± 6% and 
was proven to be suitable for the detection of inhibitors characterized by ?? for HDM2 in 
the low nanomolar range, which is the typical range of binding constants of most of the 
drug candidates developed by pharmaceutical companies to target the p53-HDM2 interac-
tion56.  
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Inhibitor ????(nM) ????????? (nM) ?? (nM) ?? ref. (nM) Solubility (μM)  
1CFY 331 ± 67 258 ± 37 2.3 ± 0.5 2125 <4[a] 
5CGU 205 ± 12 74 ± 6 0.7 ± 0.1 2125 120[a] 
Nutlin 3a ~ 20 ·103 <10 ·103 <90 90116, 9125 <130[b]  
sMTide CIS 212 ± 38 166 ± 24 1.5 ± 0.3 (7, sMTide-02A123) 240[a] 
D-peptide ~ 5 ·103 <5 ·103 <45 (53,  DPMI?124) n.d. 
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The poor solubility of the peptide p5315-29 made the measure of its ???????? impossible by 
direct titration with the sensor. The ?????of the latter was estimated by replacing the con-
stants of with the values calculated for one of the inhibitors (e.g. Nutlin 3a) in the titration 
experiment: 
???? ? ?
????????????????
???????????
? ??????????????????
????????
????? ? ?????? ? ?????? 
The ??????????? listed in Table 4:2 were calculated on the basis of this value of ???? and they 
are in close agreement with those found in literature. This value was significantly higher 
than the one obtained for the HCA-based sensor (cfr. Chapter 3.3.3). 
4.3.2 In vitro opening kinetics of the sensor in presence of inhibitors 
of the interaction p53-HDM2 
The in vitro characterization of the p53-based sensor was complemented with the meas-
urements of the opening kinetics at 37°C upon addition of inhibitors. The compounds were 
tested at the highest concentration employed in the titration experiment: as visible in the 
titration curves of Figure 4:7, the concentration was saturating for sMTide CIS, right at 
the limit of saturation for 1CFY and below saturation for 5CGU, Nutlin 3a and D-peptide. 
The FRET-ratio curve against time for each inhibitor shown in Figure 4:8 required to be fit 
with a bi-exponential function (cfr. Chapter 6.2.4): the first component mainly describes 
the opening of the sensor protein (first part of the curve) and the second component de-
scribes a slight increase of FRET ratio over the time of the experiment that was more pro-
nounced with some inhibitors and that could not be rationalized (end of the curve). For 
each inhibitor, the half-life of the first exponential component of the fitting was calculated 
as mean and standard deviation of three independent experiments and reported in Table 
4:3.  
 
 
Table 4:3 In vitro opening half-lives of the first 
component of the bi-exponential fitting function 
of the p53- based sensor in presence of inhibitors 
at 37°C.  
 
Figure 4:8 Example of opening kinetics in vitro of the p53-based sensor in presence of the inhibitors or HEPES 
buffer. 
The results of the experiment showed that the fastest opening kinetics were attained with 
5CGU, Nutlin 3a and D-peptide, despite the fact that these inhibitors were employed at 
undersaturating concentrations. This showed that, contrary to what was obtained with the 
Inhibitor ??????????  (s) in vitro 
1CFY  
(2.5 μM) 217 ± 12 
5CGU  
(10 μM) 9.4 ± 0.2 
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(75 μM) 12.0 ± 0.4 
sMTide CIS 
(5 μM) 43 ± 13 
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HCA-based sensor (cfr. Chapter 3.3.4), the unbinding of the internal peptide ligand was 
fast enough to allow the differentiation between the sensor's binding kinetics of sMTide 
CIS and 1CFY versus those of the fast binders 5CGU, Nutlin 3a and D-peptide. Unfortu-
nately the presence of a dead time of 15 seconds between the addition of inhibitor and the 
beginning of the fluorescence recording prevented the precise measurement of the koff of 
the internal p53-peptide, which however was estimated higher than 60·10-3 s-1. Slower 
sensor's opening kinetics were obtained with the inhibitors sMTide CIS and 1CFY, which 
also required an Hill's coefficient equal to 2 in the fitting of the titration curves: these two 
effects might be related, but further investigation would be necessary for drawing any rel-
evant conclusion. 
4.4 Sensing inhibitors of the interaction p53-HDM2 in cellulo 
To verify the applicability of the biosensor for intracellular detection of disruptors of the 
p53-HDM2 interaction, a doxycycline-inducible U2OS cell line was generated and tested 
in both titration and kinetic experiments, exactly as described in Chapter 3.4 for the sensor 
for HCA inhibitors. The U2OS cell line was particulary suitable for the validation of the 
biosensor: it expresses wild-type p53 and normal levels of the HDM2 protein126 and it is 
therefore considered as a good background cell line for a p53-based probe. The sensor 
showed a relatively homogeneous cellular distribution (cfr. Figure 4:9). 
 
Figure 4:9 Example of microscopy images of the U2OS cell line expressing the p53-based sensor. After CFP 
excitation, the CFP emission image (A) and the YPet emission image (B) were registered. 
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4.4.1 In cellulo titration of the p53-HDM2 interaction inhibitors 
Intracellular titration experiments were performed with all the inhibitors previously char-
acterized in vitro except for compound 1CFY, considered unsuitable for cellular assays 
because of its low solubility. As visible in Figure 4:10, the titration showed that the p53-
based sensor responded to the inhibitors in a dose-dependent manner, as expected. 
 
Table 4:4 Comparison between in cellulo and in 
vitro C50s of the p53-HDM2 interaction inhibitors. 
 
Figure 4:10 In cellulo fluorescence titration curve of 
different inhibitors with the p53-based sensor. 
 
The similarity between the in cellulo C50 of 5CGU and of Nutlin 3a did not reflect the dif-
ference of two orders of magnitude measured in vitro: this result suggested that in the cell 
line the sensor was titrated instead of the inhibitors, because presumably its doxycycline-
induced intracellular concentration reached levels comparable to the C50 of the compounds 
(around 3 μM). However, a direct measure of the intracellular sensor's concentration would 
be necessary to confirm this hypothesis. 
Interestingly, the highest concentration of sMTide CIS employed in the titration (40 μM) 
showed a high degree of cytotoxicity against the U2OS cell line: in just 2h of incubation 
this concentration of compound triggered the acute death of approximatively 60-70% of 
the cells (estimation by eye, cfr. Figure 4:11). 
 
 
 
 
 
 
 
 
Figure 4:11 Microscopy images of the U2OS cell line 2h after incubation with sMTide CIS 40 μM. After CFP 
excitation, the CFP emission image (A) and the YPet emission image (B) were registered. 
Nevertheless, the FRET-ratio could still be measured in the surviving cells, and this al-
lowed to complete the curve and to get a plausible estimation of its C50 around 3 μM. This 
toxic effect was observed only for the peptide sMTide CIS at concentration above 10 μM 
and was also monitored in time-lapse imaging experiments. 
Inhibitor C50 in cellulo (μM) 
C50 in vitro 
(nM) 
5CGU 3 ± 2 205 ± 12 
Nutlin 3a 2.8 ± 0.4 ~ 20 ·103 
sMTide CIS ~3.0 ± 0.6 212 ± 38 
D-peptide n.d. ~ 5 ·103 
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Another important result of the titration experiment consisted in the unresponsiveness of 
the intracellular sensor to the incubation with D-peptide (cfr. Figure 4:10, green dots), 
which might prove that the peptide is as poorly permeable to the cell membrane as its 
analogue DPMI? peptide124. As this latter moreover, when applied to the cells the D-peptide 
did not show any toxicity either in the titration or in kinetic experiments. 
Overall, the p53-based sensor exhibited a good intracellular FRET-ratio change of about 
170% with sMTide CIS and 130% with compounds 5CGU and Nutlin 3a. These values were 
close to the one obtained in vitro and were optimal to allow reliable fluorescence microscopy 
measurements of the cell entry kinetics of the small molecule and peptide inhibitors in 
hand. 
4.4.2 In cellulo kinetic characterization of the sensor in presence of in-
hibitors of the interaction p53-HDM2 
The p53-based sensor was successively tested for time-resolved in cellulo sensing of the 
inhibitors, as described in Chapter 3.4.2 for the HCA-based sensor: the cell line was seeded 
in 96-well plates, the compounds were added at suitable concentrations (below the limit of 
solubility and toxicity) and the time-lapse microscopy imaging was started. Also, washout 
experiments were performed on the cells incubated with small molecule inhibitors, which 
displayed fast kinetics. On the other hand, they were not performed on the cells incubated 
with peptidic inhibitors: the hours-long incubation in HBSS nutriment-free buffer required 
in this case, in fact, was likely to trigger undesired cellular stress responses. 
 
 
 
 
Figure 4:12 Opening kinetics measured by live cell 
imaging of the intracellular p53-based sensor in 
presence of (A) 5CGU 100 μM, Nutlin 3a 100 μM or 
(C) sMTide CIS 10 μM, D-peptide 10 μM or HBSS 
buffer. (B) Closing kinetics after removal of the small 
molecule inhibitors and after incubation with fresh 
HBSS buffer. 
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Table 4:5 Comparison between the opening half-lives measured in cellulo and in vitro of the p53-based sensor 
in presence of inhibitors. 
In accordance with what expected following the results of the in vitro characterization, the 
fast opening kinetics of the p53-based sensor allowed the differentiation between the cell 
entry rates of the small molecule inhibitors tested (cfr. Figure 4:12 (A)), even though a 
precise measurement of the maximal intracellular sensor opening rate was prevented by 
the presence of a deadtime of about 15 seconds between the addition of inhibitor and the 
beginning of the fluorescence microscopy imaging.  
Despite the technical limitations, we could observe that the opening of the intracellular 
sensor triggered by the addition of Nutlin 3a at 100 μM to the cells took place in less than 
10 seconds, which is in agreement with previously published data on the intracellular 
inhibition kinetics of p53–HDM2 interaction induced by Nutlin 3127. Compound 5CGU, 
which in vitro exhibited a C50 two orders of magnitude lower than Nutlin 3a and comparable 
sensor interaction kinetics, opened the intracellular sensor 8 to 18 times slower than Nut-
lin 3a, the applied concentration of the inhibitors being equal. This outcome reflects an 
inferior ability of 5CGU to transit through the cell membrane, presumably because of the 
presence of a carboxylic acid in the molecular structure of the compound (cfr. Figure 4:6). 
As for sMTide CIS, the intracellular sensor's opening half-life obtained with the peptide 
was remarkably slow compared to that of the small molecules (cfr. Figure 4:12 (C)): at the 
same concentration 5CGU and Nutlin 3a enter the cells 2 to 18 times faster. This difference 
might reflect the fact that the peptide is internalized via active transport, since endosomal 
release has to be accomplished before the opening of the cytosolic sensor can take place.  
The cell clearance rates of the two small molecule inhibitors were also evaluated (cfr. Figure 
4:12 (B)). Interestingly, Nutlin 3a showed to be able to move very fast both in and out the 
cellular space, whereas no FRET-ratio decrease was detected in the cells treated with 
5CGU following the incubation with fresh HBSS buffer: the compound seemed to be re-
tained in the intracellular environment, in a similar way as acetazolamide (cfr. Chapter 
3.4.2).  
4.4.3 Conclusions and outlook  
In this chapter the design and the performances of a novel FRET-based biosensor for dis-
ruptors of the p53-HDM2 interaction is presented. The sensor consists in a single-chain 
fusion protein molecule, which offers the advantage of being entirely genetically encodable 
and not requiring any labelling with synthetic molecules. Moreover, as additional benefit 
with respect to previously published p53-HDM2 PPI targeting systems127, 128, our biosensor 
Inhibitor ?????????(s)  in cellulo 
??????????  (s)  
in vitro 
5CGU  
(100 μM) 115 ± 7 n.d. 
Nutlin 3a  
(100 μM) 6 ± 1 n.d. 
5CGU  
(10 μM) 651 ± 94 9.4 ± 0.2 
Nutlin 3a  
(10 μM) 83 ± 16 n.d. 
 sMTide CIS 
(10 μM) 1518 ± 92 43 ± 13 
D-peptide  
(10 μM) n.d. 12 ± 4 
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provides an intramolecular ratiometric readout, which eliminates the problem of the rela-
tive stoichiometry of the FRET-partners129.  
At first, the sensor was tested and characterized in vitro, where it displayed a high and 
reproducible FRET-ratio change of about 170%, very fast opening kinetics and a response 
that falls in an appropriate inhibitors' concentration window (high nM to high μM), where 
most of the developed p53-HDM2 interaction disruptors show therapeutic efficacy. After-
wards, in live cells fluorescence imaging, the sensor maintained a high FRET-ratio dynamic 
range and allowed to follow in real-time the disruption of the intra-sensor p53-HDM2 in-
teraction triggered by a selection of small molecule and peptidic inhibitors. These assays 
revealed the low cellular permeability of the D-peptide and important differences between 
the cell entry kinetics of small molecule and peptide inhibitors. Two compounds with 
equally fast binding kinetics in vitro, 5CGU and Nutlin 3a, showed significative differences 
in cellular uptake rates, which might be explained by considerations on their chemical 
structure. 
The described biosensor presents itself as a valuable technology for time-resolved moni-
toring of the cellular uptake of various unmodified p53-HDM2 PPI inhibitors. Its simplicity 
and the minimal manipulation required for cellular assays makes it a promising tool for 
characterizing new drugs, improving their rational design and, eventually, for high-
throughput screening. Further work on the project would focus on the applicability of the 
sensor for reliable measurements of intracellular inhibitors' concentration, which would 
require a tighter control of the sensor's expression level in the cells to keep them below the 
range of ??? of the compounds of interest. Finally, the presented strategy, thanks to its 
versatility and practicality, could be adapted to investigate other protein-protein interac-
tions and their inhibition in living cells.  
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 General conclusions 
The existing techniques to estimate the cellular permeability of molecules when they are 
non-cell based often fail in properly mimicking the complexity of biological membranes. 
On the other hand, cell-based techniques are too laborious, cell-type specific and have 
poor temporal-resolution. The work presented in this thesis aims to offer an alternative 
method. 
The two biosensors described here enable one to evaluate in real-time in living cells the 
extent and the kinetics of cellular uptake and clearance of underivatized molecules. Two 
big families of clinically relevant, underivatized compounds were targeted: inhibitors of the 
enzyme human carbonic anhydrase II (HCAII), most of which are already commercialized 
drugs, and inhibitors of the p53-HDM2 interaction, whose disruptors are nowadays pro-
tagonists of several cancer therapies. Our strategy was proved to be versatile and adaptable 
to the characterization of inhibitors of both ligand-protein and protein-protein interactions. 
Compounds belonging to the same family could be compared with respect to their binding 
constants to the target and, most importantly, with respect to their ability to access and 
exit the intracellular space. Significative differences were detected, could often be ration-
alized based on the chemical structure of the molecules and resulted in agreement with 
previously published data, when available. 
Pharmaceutical companies have always had great interest in improving the efficiency and 
reducing the time and costs of drug candidates' profiling. The biosensors presented in the 
thesis can find applications in this context, for the establishement of fast, cheap, non-
invasive and versatile assays that allow the combined evaluation of biological activity and 
cellular permeability of potential drug leads. Finally, thanks to its modular design, our 
technology can eventually be adapted to the detection of different families of clinically rel-
evant chemical entities. 
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 Materials and Methods 
6.1 Chemical synthesis 
6.1.1 General information 
All solvents and chemicals were purchased from Sigma-Aldrich, Fisher Scientific, Merck, 
Fluka, Acros and were used without any further purification. Reverse-phase preparative 
high-pressure liquid chromatography (Prep-HPLC) was performed on a Dionex system 
equipped with an UltiMate 3000 pump and an UV D170U UV-Vis detector for product 
visualization on a Waters SunFire Prep C18 OBD 5 ?m 10×150 mm Column. Buffer A: 
0.1% TFA in H2O Buffer B: acetonitrile. Typical gradient was from 0% to 100% B within 25 
min with 4 ml min-1 flow. 1H and 13C nuclear magnetic resonance (NMR) spectra were 
recorded at room temperature respectively on a Bruker DPX 400 (400 MHz) and on a 
Bruker Avance III HD 600 (600 MHz), with chemical shifts (?) reported in ppm relative to 
the solvent residual signals. CD2Cl2: ?H 5.3 ppm, ?C 53.84; D6-DMSO: ?H 2.5 ppm, ?C 
39.5 ppm; CD3OD: ?H 3.31 ppm, ?C 49.0 ppm. Coupling constants are reported in Hz. 
High resolution mass spectra (HRMS) were measured on a Micromass Q-TOf Ultima spec-
trometer with electron spray ionization (ESI). 
6.1.2 Synthesis of compounds 
N
H
N
N
N
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O H
N O
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21  
(9H-fluoren-9-yl)methyl (6-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-6-
oxohexyl)carbamate (7) 6-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)hexanoic acid (106 
mg, 300 μmol) was dissolved in 0.4 ml of DMSO; DIPEA (105 μl, 600 μmol) and TSTU (100 
mg, 330 μmol) were then added, and the mixture was stirred during 15 min at room tem-
perature. A solution of 6-((4-(aminomethyl)benzyl)oxy)-9H-purin-2-amine (21*, 81 mg, 300 
μmol) in 0.4 ml of DMSO was added to the previous mixture and the stirring continued for 
other 60 min. 0.3 ml of H2O and 250 μl of glacial acetic acid  were then added and the 
mixture was purified by preparative HPLC. The fractions containing the product were 
checked by HRMS (ESI) and lyophilized to give compound 7 (54.0 mg, 89 μmol, 30%). 
[HRMS (ESI) calculated for C34H36N7O4+ [M+H]+ 606.2823; found 606.2823. 1H NMR (400 
MHz, DMSO-d6) ? 8.43 (s, 1 H), 8.33 (t, 1 H, J = 5.9 Hz), 7.89 (d, 2 H, J = 7.4 Hz), 7.69 (d, 
2 H, J = 7.4 Hz), 7.49 (d, 2 H, J = 8.0 Hz), 7.41 (t, 2 H, J = 7.4 Hz), 7.33 (td, 2 H, J = 1.1, 
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7.4 Hz), 7.29 (d, 2 H, J = 8.0 Hz), 5.52 (s, 2 H), 4.3 (d, 2 H, J = 6.9 Hz), 4.27 (d, 2 H, J = 
5.9 Hz), 4.21 (t, 1 H, J = 6.9 Hz), 3.00-2.94 (m, 2 H), 2.13 (t, 2 H, J = 7.4 Hz), 1.56-1.48 
(m, 2 H), 1.44-1.37 (m, 2 H), 1.28-1.20 (m, 2 H)].  
*21 was synthesized as reported before45. 
 
6-amino-N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)hexanamide (8) Compound 
7 (28 mg, 46.2 μmol) was dissolved in 1 ml of a mixture DBU/ACN 1:10 and stirred at 
room temperature for 30 min; then 250 μl of glacial acetic acid were added to neutralize 
the base. After solvent evaporation the mixture was dissolved in 1.5 ml of DMSO, purified 
by preparative HPLC and lyophilized to give compound 8 (16 mg, 42 μmol, 91%). [HRMS 
(ESI) calculated for C19H26N7O2+ [M+H]+ 384.2142; found 384.2147. 1H NMR (400 MHz, 
DMSO-d6) ? 8.37 (t, 1 H, J = 5.9 Hz), 8.29 (s, 1 H), 7.72 (s, 2 H), 7.49 (d, 2 H, J = 8.0 Hz), 
7.28 (d, 2 H, J = 8.0 Hz), 5.52 (s, 2 H), 4.27 (d, 2 H, J = 5.9 Hz), 2.81-2.73 (m, 2 H), 2.14 
(t, 2 H, J = 7.4 Hz), 1.57-1.49 (m, 4 H), 1.33-1.24 (m, 2 H)]. 
 
N-(6-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-3-sul-
famoylbenzamide (1a) 3-sulfamoylbenzoic acid (22*, 13 mg, 65 μmol) was dissolved in 
0.7 ml of DMSO together with HBTU (25 mg, 65 μmol) and DIPEA (66 μl, 379 μmol); the 
mixture was stirred at room temperature for 15 min. Compound 8 was then added and 
the reaction was left under stirring during 30 min at room temperature. 200 ?l of H2O and 
200 ?l of glacial acetic acid were added. The reaction mixture was purified by preparative 
HPLC and lyophilized to give the product 1a (18 mg, 32 μmol, 76%). [HRMS (ESI) calculated 
for C26H31N8O5S+ [M+H]+ 567.2133; found 567.2139. 1H NMR (400 MHz, DMSO-d6) ? 8.63 
(t, 1 H, J = 5.9 Hz), 8.26-8.23 (m, 2 H), 7.98-7.95 (dm, 1 H, J = 7.8 Hz), 7.88 (ddd, 1 H, J 
= 7.8, 1.8, 1.1 Hz), 7.60 (t, 1 H, J = 7.8 Hz), 7.41 (d, 2 H, J = 8.0 Hz), 7.37 (s, 2 H), 7.20 (d, 
2 H, J = 8.0 Hz), 5.44 (s, 2 H), 4.19 (d, 2 H, J = 5.9 Hz), 3.22-3.17 (m, 2 H), 2.08 (t, 2 H, J 
= 7.4 Hz), 1.53-1.43 (m, 4 H), 1.27-1.17 (m, 2 H). 13C NMR (151 MHz, MeOD) ? 174.6, 
167.2, 159.7, 144.3, 139.6, 135.4, 134.0, 130.1, 128.8, 127.4, 124.7, 69.4, 42.3, 39.6, 
35.5, 28.7, 26.2, 25.3].  
*22 was synthesized as reported before50. 
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N-(6-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-4-sul-
famoylbenzamide (1b) 4-sulfamoylbenzoic acid (16 mg, 80 μmol) was dissolved in 0.75 ml 
of DMSO together with TSTU (8 mg, 26 μmol) and DIPEA (20 μl, 209 μmol); the mixture 
was stirred at room temperature for 15 min. Compound 8 (10 mg, 26 μmol) was then added 
and the reaction was left under stirring during 30 min at room temperature. 200 ?l of H2O 
and 200 ?l of glacial acetic acid were added. The reaction mixture was purified by prepar-
ative HPLC and lyophilized to give the product 1b (3 mg, 5.3 μmol, 20%). [HRMS (ESI) 
calculated for C26H31N8O5S+ [M+H]+ 567.2133; found 567.2139. 1H NMR (600 MHz, MeOD) 
? 8.32 (s, 1 H), 7.98-7.93 (m, 4 H), 7.50 (d, 2 H, J = 8.1 Hz), 7.34 (d, 2 H, J = 8.1 Hz), 5.63 
(s, 2 H), 4.39 (s, 2 H), 3.40 (t, 2 H, J = 7.1 Hz), 2.68 (s, 1 H), 2.29 (t, 2 H, J = 7.3 Hz), 1.77-
1.62 (m, 4 H), 1.48-1.40 (m, 2 H). 13C NMR (151 MHz, MeOD) ? 174.6, 167.4, 146.3, 139.6, 
137.8, 128.8, 127.5, 127.4, 125.9, 69.3, 42.3, 39.6, 35.5, 28.7, 26.2, 25.6, 25.2]. 
 
N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-1-oxo-1-(3-sulfamoylphenyl)-
6,9,12,15,18,21-hexaoxa-3-azatetracosan-24-amide (2a) Compound 22 (25 mg, 125 
μmol) was dissolved in 1 ml of DMSO together with HBTU (47 mg, 125 μmol) and DIPEA 
(72 μl, 415 μmol); the mixture was stirred at room temperature for 15 min. 1-amino-N-(4-
(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-3,6,9,12,15,18-hexaoxahenicosan-21-amide 
(9*, 50 mg, 83 μmol) was then added and the reaction was left under stirring during 30 
min at room temperature. 200 ?l of glacial acetic acid were added. The reaction mixture 
was purified by preparative HPLC and lyophilized to give the product 2a (60 mg, 76 μmol, 
92%). [HRMS (ESI) calculated for C35H49N8O11S+ [M+H]+ 789.3236; found 789.3243. 1H 
NMR (400 MHz, DMSO-d6) ? 8.78 (t, 1 H, J = 5.4 Hz), 8.47 (s, 1 H), 8.39 (t, 1 H, J = 6.0 
Hz), 8.31 (t, 1 H, J = 1.7 Hz), 8.05 (dt, 1 H, J = 7.8, 1.1 Hz), 7.96 (ddd, 1 H, J = 7.8, 1.7, 
1.1 Hz), 7.67 (t, 1 H, J = 7.8 Hz), 7.49 (d, 2 H, J = 8.1 Hz), 7.45 (s, 2 H), 7.29 (d, 2 H, J = 
8.1 Hz), 5.53 (s, 2 H), 4.28 (d, 2 H, J = 6.0 Hz), 3.63 (t, 2 H, J = 6.4 Hz), 3.56-3.41 (m, 24 
H), 2.38 (t, 2 H, J = 6.4 Hz). 13C NMR (101 MHz, DMSO-d6) ? 170.7, 166.7, 165.6, 159.2, 
159.0, 158.6, 145.1, 144.9, 140.6, 135.5, 134.2, 132.9, 132.0, 130.6, 130.2, 130.1, 129.6, 
129.5, 128.6, 127.7, 126.9, 125.2, 70.2, 70.1, 70.0, 69.3, 69.0, 67.3.]. 
*9 was synthesized as reported before130. 
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N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-1-oxo-1-(3-sulfamoylphenyl)-
6,9,12,15,18,21,24,27,30,33,36,39-dodecaoxa-3-azadotetracontan-42-amide (2b) 
Compound 22 (6 mg, 30 μmol) was dissolved in 0.75 ml of DMSO together with HBTU (11 
mg, 30 μmol) and DIPEA (27 μl, 155 μmol); the mixture was stirred at room temperature 
for 15 min. 1-amino-N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-amide (10*, 18 mg, 20 
μmol) was then added and the reaction was left under stirring during 30 min at room 
temperature. 50 ?l of glacial acetic acid were added. The reaction mixture was purified by 
preparative HPLC and lyophilized to give the product 2b (9.5 mg, 9 μmol, 43%). [HRMS 
(ESI) calculated for C47H73N8O17S+ [M+H]+ 1053.4809; found 1053.4813. 1H NMR (400 MHz, 
DMSO-d6) ? 8.79 (t, 1 H, J = 5.4 Hz), 8.48 (s, 1 H), 8.40 (t, 1 H, J = 5.7 Hz), 8.32 (d, 1 H, J 
= 0.7 Hz), 8.06 (dd, 1 H, J = 7.8, 0.9 Hz), 7.97 (dd, 1 H, J = 7.8, 0.9 Hz), 7.68 (t, 1 H, J = 
7.8 Hz), 7.50 (d, 2 H, J = 7.8 Hz), 7.43 (s, 2 H), 7.29 (d, 2 H, J = 7.8 Hz), 5.53 (s, 2 H), 4.29 
(d, 2 H, J = 5.9 Hz), 3.63 (t, 2 H, J = 6.4 Hz), 3.60-3.40 (m, 48 H), 2.39 (t, 2 H, J = 6.4 Hz). 
13C NMR (151 MHz, DMSO-d6) ? 170.6, 165.5, 144.9, 135.5, 130.6, 129.6, 129.3, 128.6, 
127.7, 125.2, 82.3, 70.2, 69.3, 67.3, 42.3, 36.6]. 
*10 was synthesized as reported before44. 
 
(9H-fluoren-9-yl)methyl (1-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)phenyl)-3,10-di-
oxo-12,15-dioxa-2,9-diazaheptadecan-17-yl)carbamate (11) 1-(9H-fluoren-9-yl)-3-oxo-
2,7,10-trioxa-4-azadodecan-12-oic acid (117 mg, 303 μmol) was dissolved in 2 ml of DMSO 
together with TSTU (100 mg, 332 μmol) and DIPEA (131 μl, 758 μmol); the mixture was 
stirred at room temperature for 30 min. Compound 8 (116 mg, 303 μmol) was then added 
and the reaction was left under stirring during 60 min at room temperature. 300 ?l of 
glacial acetic acid were added. The solution was extracted with 2×40 ml EtOAc and 2×50 
ml H2O. The organics were dried over Mg2SO4, filtered and concentrated. The reaction mix-
ture was purified by preparative HPLC and lyophilized to give the product 11 (150 mg, 200 
μmol, 66%). [HRMS (ESI) calculated for C40H47N8O7+ [M+H]+ 751.3562; found 751.3566. 1H 
NMR (400 MHz, DMSO-d6) ? 8.30 (t, 1 H, J = 5.9 Hz), 7.90 (d, 2 H, J = 7.5 Hz), 7.70 (d, 2 
H, J = 7.5 Hz), 7.67-7.64 (m, 1 H), 7.48 (d, 2 H, J = 8.0 Hz), 7.42 (t, 2 H, J = 7.4 Hz), 7.37-
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7.31 (m, 3 H), 7.27 (d, 2 H, J = 8.0 Hz), 5.50 (s, 2 H), 4.30 (d, 2 H, J = 6.8 Hz), 4.26 (d, 2 
H, J = 5.7 Hz), 4.22 (m, 1 H), 3.86 (s, 2 H), 3.43 (t, 2 H, J = 5.9 Hz), 3.18-3.14 (m, 2 H), 
3.11-3.06 (m, 2 H), 2.12 (t, 2 H, J = 7.4 Hz), 1.55-1.48 (m, 2 H), 1.45-1.38 (m, 2 H), 1.27-
1.21 (m, 2 H)]. 
 
N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-6-(2-(2-(2-aminoethoxy)ethoxy)ac-
etamido)hexanamide (12) Compound 11 (34 mg, 45 μmol) was dissolved in 2 ml of a 
mixture DBU/ACN 1:10 and stirred at room temperature for 45 min; then 300 μl of glacial 
acetic acid were added to neutralize the base. After solvent evaporation the mixture was 
dissolved in 1.5 ml of DMSO, purified by preparative HPLC and lyophilized to give com-
pound 12 (22 mg, 42 μmol, 93%). [HRMS (ESI) calculated for C25H37N8O5+ [M+H]+ 529.2881; 
found 529.2886. 1H NMR (400 MHz, DMSO-d6) ? 8.32 (t, 1 H, J = 5.9 Hz), 7.75-7.72 (m, 3 
H), 7.48 (d, 2 H, J = 8.1 Hz), 7.28 (d, 2 H, J = 8.1 Hz), 5.49 (s, 2 H), 4.28 (d, 2 H, J = 5.8 
Hz), 3.90 (s, 2 H), 3.12-3.07 (m, 2 H), 3.02-2.98 (m, 2 H), 2.14 (t, 2 H, J = 7.4 Hz), 1.57-
1.50 (m, 2 H), 1.47-1.40 (m, 2 H), 1.29-1.21 (m, 2 H)]. 
 
N-(1-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)phenyl)-3,10-dioxo-12,15-dioxa-2,9-di-
azaheptadecan-17-yl)-3-sulfamoylbenzamide (3a) Compound 22 (6.5 mg, 31 μmol) was 
dissolved in 0.75 ml of DMSO; DIPEA (4.5 μl, 26 μmol), EDC·Cl (6.5 mg, 34 μmol) and HOBt 
(3.5 mg, 26 μmol) were then added, and the mixture was stirred during 3 min at room 
temperature. Compound 12 (14 mg, 26 μmol) was added to the previous mixture and the 
stirring continued for other 60 min. The mixture was purified by preparative HPLC. The 
fractions containing the product were checked by HRMS (ESI) and lyophilized to give com-
pound 3a (13 mg, 18 μmol, 70%). [HRMS (ESI) calculated for C32H42N9O8S+ [M+H]+ 
712.2872; found 712.2876. 1H NMR (400 MHz, MeOD) ? 8.37 (s, 1 H), 8.07-8.02 (m, 2 H), 
7.64 (t, 1 H, J = 7.8 Hz), 7.53 (d, 2 H, J = 8.0 Hz), 7.34 (d, 2 H, J = 8.0 Hz), 5.63-5.62 (m, 
2 H), 4.39 (s, 2 H), 3.99 (s, 2 H), 3.73-3.69 (m, 6 H), 3.64-3.60 (m, 2 H), 3.19 (t, 2 H, J = 
7.1 Hz), 2.25 (t, 2 H, J = 7.4 Hz), 1.67-1.60 (m, 2 H), 1.54-147 (m, 2 H), 1.37-1.31 (m, 2 
H). 13C NMR (101 MHz, MeOD) ? 174.6, 171.2, 167.4, 144.3, 139.7, 135.2, 133.9, 130.3, 
129.1, 128.9, 127.4, 124.8, 70.6, 69.8, 69.5, 69.1, 42.3, 39.6, 39.0, 38.4, 35.5, 28.8, 26.1, 
25.2]. 
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N-(1-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)phenyl)-3,10-dioxo-12,15-dioxa-2,9-di-
azaheptadecan-17-yl)-4-sulfamoylbenzamide (3b) 4-sulfamoylbenzoic acid (4 mg, 20 
μmol) was dissolved in 0.75 ml of DMSO; DIPEA (3 μl, 15 μmol), EDC·Cl (4 mg, 20 μmol) 
and HOBt (2 mg, 15 μmol) were then added, and the mixture was stirred during 3 min at 
room temperature. Compound 12 (8 mg, 15 μmol) was added to the previous mixture and 
the stirring continued for other 60 min. The mixture was purified by preparative HPLC. 
The fractions containing the product were checked by HRMS (ESI) and lyophilized to give 
compound 3b (10 mg, 14 μmol, 93%). [HRMS (ESI) calculated for C32H42N9O8S+ [M+H]+ 
712.2872; found 712.2870. 1H NMR (400 MHz, MeOD) ? 7.99-7.95 (m, 4 H), 7.64 (s, 0 H), 
7.53 (d, 2 H, J = 8.0 Hz), 7.34 (d, 2 H, J = 8.0 Hz), 5.64-5.63 (m, 2 H), 4.39 (s, 2 H), 3.98 
(s, 2 H), 3.73-3.69 (m, 6 H), 3.64-3.60 (m, 2 H), 3.20 (t, 2 H, J = 7.1 Hz), 2.25 (t, 2 H, J = 
7.4 Hz), 1.68-1.60 (m, 2 H), 1.55-1.48 (m, 2 H), 1.37-1.31 (m, 2 H). 13C NMR (101 MHz, 
MeOD) ? 128.8, 127.6, 127.4, 125.9, 70.6, 69.8, 69.2, 69.1, 42.3, 39.6, 39.0, 38.4, 35.5, 
28.8, 26.1, 25.2]. 
 
(9H-fluoren-9-yl)methyl (6-((4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)ben-
zyl)amino)-6-oxohexyl)carbamate (13) 6-((((9H-fluoren-9-yl)methoxy)car-
bonyl)amino)hexanoic acid (80 mg, 226 μmol) was dissolved in 2.5 ml of DMSO together 
with TSTU (75 mg, 250 μmol) and DIPEA (80 μl, 460 μmol); the mixture was stirred at room 
temperature for 30 min. Compound 23 (60 mg, 226 μmol) was then added and the reaction 
was left under stirring during 60 min at room temperature. 300 ?l of glacial acetic acid 
were added. The solution was extracted with 2×30 ml EtOAc and 2×50 ml H2O. The organ-
ics were dried over Mg2SO4, filtered and concentrated. The reaction mixture was purified 
by preparative HPLC and lyophilized to give the product 13 (70 mg, 117 μmol, 52%). [HRMS 
(ESI) calculated for C34H37ClN4O4+ [M+H]+ 600.2498; found 600.2372. 1H NMR (400 MHz, 
DMSO-d6) ? 8.30 (t, 1 H, J = 5.9 Hz), 7.90 (d, 2 H, J = 7.5 Hz), 7.69 (d, 2 H, J = 7.5 Hz), 
7.44-7.38 (m, 4 H), 7.34 (td, 2 H, J = 7.5, 1.0 Hz), 7.30-7.24 (m, 3 H), 7.11 (s, 2 H), 6.13 
(s, 1 H), 5.29 (s, 2 H), 4.30 (d, 2 H, J = 6.8), 4.26 (d, 2 H, J = 5.9 Hz), 4.21 (t, 1 H, J = 6.8), 
3.00-2.95 (m, 2 H), 2.13 (t, 2 H, J = 7.4 Hz), 1.56-1.49 (m, 2 H), 1.44-1.37 (m, 2 H), 1.28-
1.21 (m, 2 H)]. 
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6-amino-N-(4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)benzyl)hexanamide (14) 
Compound 13 (70 mg, 117 μmol) was dissolved in 2 ml of a mixture DBU/ACN 1:10 and 
stirred at room temperature for 45 min; then 300 μl of glacial acetic acid were added to 
neutralize the base. After solvent evaporation the mixture was dissolved in 2 ml of DMSO, 
purified by preparative HPLC and lyophilized to give compound 14 (42 mg, 106 μmol, 90%). 
[HRMS (ESI) calculated for C18H25ClN5O2+ [M+H]+ 378.1691; found 378.1690. 1H NMR (400 
MHz, DMSO-d6) ? 8.30 (t, 1 H, J = 5.9), 7.38 (d, 2 H, J = 8.1 Hz), 7.25 (d, 2 H, J = 8.1 Hz), 
7.11 (s, 2 H), 6.14 (s, 1 H), 5.29 (s, 2 H), 4.25 (d, 2 H, J = 5.9 Hz), 2.12 (t, 2 H, J = 7.4 Hz), 
1.94-1.88 (m, 2 H), 1.55-1.47 (m, 2 H), 1.37-1.30 (m, 2 H), 1.27-1.23 (m, 2 H)]. 
 
(9H-fluoren-9-yl)methyl (1-(4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)phenyl)-
3,10-dioxo-12,15-dioxa-2,9-diazaheptadecan-17-yl)carbamate (15) 1-(9H-fluoren-9-
yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acid (40 mg, 104 μmol) was dissolved in 2 ml 
of DMSO; DIPEA (17 μl, 97 μmol), EDC·Cl (22 mg, 113 μmol) and HOBt (12 mg, 87 μmol) 
were then added, and the mixture was stirred during 3 min at room temperature. Com-
pound 14 (33 mg, 87 μmol) was added to the previous mixture and the stirring continued 
for other 60 min. The mixture was purified by preparative HPLC. The fractions containing 
the product were checked by HRMS (ESI) and lyophilized to give compound 15 (40 mg, 54 
μmol, 62%). [HRMS (ESI) calculated for C39H45ClN6NaO7+ [M+Na]+ 767.2930; found 
767.2932. 1H NMR (400 MHz, DMSO-d6) ? 8.30 (t, 1 H, J = 5.9 Hz), 7.90 (d, 2 H, J = 7.5 
Hz), 7.69 (d, 2 H, J = 7.5 Hz), 7.43-7.37 (m, 4 H), 7.35-7.31 (m, 2 H), 7.24 (d, 2 H, J = 8 
Hz), 6.13 (s, 1 H), 5.28 (s, 2 H), 4.30 (d, 2 H, J = 6.7), 4.26 (d, 2 H, J = 5.6 Hz), 4.21 (t, 1 
H, J = 6.7), 3.85 (s, 2 H), 3.58-3.53 (m, 4 H), 3.18-3.13 (m, 2 H), 3.11-3.05 (m, 2 H), 2.11 
(t, 2 H, J = 7.3 Hz), 1.55-1.47 (m, 2 H), 1.45-1.38 (m, 2 H), 1.27-1.20 (m, 2 H)]. 
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N-(4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)benzyl)-6-(2-(2-(2-aminoeth-
oxy)ethoxy)acetamido)hexanamide (16) Compound 15 (40 mg, 54 μmol) was dissolved 
in 2 ml of a mixture DBU/ACN 1:10 and stirred at room temperature for 45 min; then 300 
μl of glacial acetic acid were added to neutralize the base. After solvent evaporation the 
mixture was dissolved in 2 ml of DMSO, purified by preparative HPLC and lyophilized to 
give compound 16 (27 mg, 52 μmol, 96%). [HRMS (ESI) calculated for C24H36ClN6O5+ [M+H]+ 
523.2430; found 523.2447. 1H NMR (400 MHz, DMSO-d6) ? 8.31 (t, 1 H, J = 5.9 Hz), 7.78 
(s, 2 H), 7.75-7.72 (t, 1 H, J = 5.9 Hz), 7.39 (d, 2 H, J = 8.1 Hz), 7.25 (d, 2 H, J = 8.1 Hz), 
7.11 (s, 2 H), 6.13 (s, 1 H), 5.29 (s, 2 H), 4.25 (d, 2 H, J = 5.9 Hz), 3.89 (s, 2 H), 3.62-3.59 
(m, 4 H), 3.11-3.06 (m, 2 H), 3.01-2.97 (m, 2 H), 2.13 (t, 2 H, J = 7.4 Hz), 1.56-1.48 (m, 2 
H), 1.46-1.39 (m, 2 H), 1.27-1.20 (m, 2 H)]. 
 
N-(1-(4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)phenyl)-3,10-dioxo-12,15-di-
oxa-2,9-diazaheptadecan-17-yl)-3-sulfamoylbenzamide (4a) Compound 22 (23 mg, 114 
μmol) was dissolved in 1.5 ml of DMSO; DIPEA (16 μl, 92 μmol), EDC·Cl (23 mg, 120 μmol) 
and HOBt (13 mg, 92 μmol) were then added, and the mixture was stirred during 3 min at 
room temperature. Compound 16 (48 mg, 92 μmol) was added to the previous mixture and 
the stirring continued for other 60 min. The mixture was purified by preparative HPLC. 
The fractions containing the product were checked by HRMS (ESI) and lyophilized to give 
compound 4a (15 mg, 21 μmol, 23%). [HRMS (ESI) calculated for C31H41ClN7O8S+ [M+H]+ 
706.2420; found 706.2430. 1H NMR (400 MHz, DMSO-d6) ? 8.79 (t, 1 H, J = 5.6 Hz), 8.32 
(t, 1 H, J = 1.6 Hz), 8.29 (t, 1 H, J = 5.9 Hz), 8.06 (ddd, 1 H, J = 7.8, 1.6, 1.1 Hz), 7.97 
(ddd, 1 H, J = 7.8, 1.8, 1.0 Hz), 7.70-7.65 (m, 2 H), 7.45 (s, 2 H), 7.39 (d, 2 H, J = 8.3 Hz), 
7.25 (d, 2 H, J = 8.3 Hz), 7.11 (s, 2 H), 6.14 (s, 1 H), 5.30 (s, 2 H), 4.26 (d, 2 H, J = 5.9 Hz), 
3.87 (s, 2 H), 3.61-3.57 (m, 6 H), 3.47 (q, 2 H, J = 5.7 Hz), 3.10-3.05 (q, 2 H, J = 6.8 Hz), 
2.12 (t, 2 H, J = 7.4 Hz), 1.55-1.48 (m, 2 H), 1.45-1.38 (m, 2 H), 1.26-1.19 (m, 2 H). 13C 
NMR (151 MHz, DMSO-d6) ? 172.5, 170.8, 169.4, 165.8, 163.3, 160.5, 146.7, 140.2, 137.7, 
135.1, 128.9, 128.9, 128.3, 127.7, 126.1, 94.9, 70.7, 70.7, 69.8, 69.3, 67.7, 42.2, 40.9, 
38.5, 35.7, 29.5, 26.6, 25.6.]. 
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N-(1-(4-(((2-amino-6-chloropyrimidin-4-yl)oxy)methyl)phenyl)-3,10-dioxo-12,15-di-
oxa-2,9-diazaheptadecan-17-yl)-4-sulfamoylbenzamide (4b) 4-sulfamoylbenzoic acid 
(23 mg, 114 μmol) was dissolved in 1.5 ml of DMSO; DIPEA (16 μl, 92 μmol), EDC·Cl (23 
mg, 120 μmol) and HOBt (13 mg, 92 μmol) were then added, and the mixture was stirred 
during 3 min at room temperature. Compound 16 (48 mg, 92 μmol) was added to the 
previous mixture and the stirring continued for other 60 min. The mixture was purified by 
preparative HPLC. The fractions containing the product were checked by HRMS (ESI) and 
lyophilized to give compound 4b (11 mg, 16 μmol, 17%). [HRMS (ESI) calculated for 
C31H40ClN7NaO8S+ [M+Na]+ 728.2240; found 728.2248. 1H NMR (400 MHz, DMSO-d6) ? 
8.73 (t, 1 H, J = 5.5 Hz), 8.29 (t, 1 H, J = 5.9 Hz), 8.00 (d, 2 H, J = 8.5 Hz), 7.91 (t, 2 H, J 
= 8.5 Hz), 7.66 (t, 1 H, J = 5.9 Hz), 7.49 (s, 2 H), 7.39 (d, 2 H, J = 8.2 Hz), 7.25 (d, 2 H, J 
= 8.2 Hz), 6.14 (s, 1 H), 5.30 (s, 2 H), 4.26 (d, 2 H, J = 5.9 Hz), 3.87 (s, 2 H), 3.61-3.57 (m, 
6 H), 3.46 (q, 2 H, J = 5.5 Hz), 3.08 (q, 2 H, J = 6.8 Hz), 2.12 (t, 2 H, J = 7.4), 1.55-1.48 
(m, 2 H), 1.45-1.38 (m, 2 H), 1.26-1.19 (m, 2 H). 13C NMR (151 MHz, DMSO-d6) ? 172.5, 
170.8, 169.4, 165.6, 163.2, 160.5, 158.8, 158.6, 144.8, 140.2, 135.5, 135.1, 130.6, 129.6, 
128.9, 128.6, 127.7, 125.2, 94.9, 70.7, 70.7, 70.4, 69.8, 69.3, 67.7, 42.2, 40.9, 38.5, 35.7, 
29.5, 26.6, 25.5]. 
 
N-(6-aminohexyl)-4-sulfamoylbenzamide (17) 4-sulfamoylbenzoic acid (40 mg, 200 
μmol) was dissolved in 2.5 ml of DMSO together with TSTU (72 mg, 240 μmol) and DIPEA 
(138 μl, 800 μmol); the mixture was stirred at room temperature for 30 min. Hexane-1,6-
diamine (46 mg, 400 μmol) was then added and the reaction was left under stirring during 
60 min at room temperature. 1 ml of H2O and 500 ?l of glacial acetic acid were added. The 
reaction mixture was purified by preparative HPLC and lyophilized to give the product 17 
(58 mg, 195 μmol, 98%). [HRMS (ESI) calculated for C13H22N3O3S+ [M+H]+ 300.1376; found 
300.1382. 1H NMR (400 MHz, DMSO-d6) ? 8.65 (t, 1 H, J = 5.5 Hz), 7.98 (d, 2 H, J = 8.7), 
7.90 (d, 2 H, J = 8.7), 7.62 (s, 2 H), 7.49 (s, 2 H), 3.28 (q, 2 H, J = 6.8 Hz), 2.78 (t, 2 H, J = 
7.4 Hz), 1.58-1.50 (m, 4 H), 1.36-1.31 (m, 4 H).]. 
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2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-oxo-3-((6-(4-sulfamoylben-
zamido)hexyl)amino)propane-1-sulfonic acid (18) (((9H-fluoren-9-yl)methoxy)car-
bonyl)(sulfo)alanine (16 mg, 41 μmol) was dissolved in 1.5 ml of DMSO together with TSTU 
(13 mg, 43 μmol) and DIPEA (19 μl, 110 μmol); the mixture was stirred at room temperature 
for 30 min. Compound 17 (11 mg, 37 μmol) was then added and the reaction was left 
under stirring during 60 min at room temperature. 100 ?l of glacial acetic acid were added. 
The reaction mixture was purified by preparative HPLC and lyophilized to give the product 
18 (22 mg, 33 μmol, 80%). [HRMS (ESI) calculated for C31H36N4NaO9S2+ [M+Na]+ 695.1816; 
found 695.1825. 1H NMR (400 MHz, MeOD) ? 8.00-7.95 (m, 4 H), 7.80 (d, 2 H, J = 7.4 Hz), 
7.71-7.69 (m, 2 H), 7.42-7.38 (m, 2 H), 7.35-7.31 (m, 2 H), 4.50 (dd, 1 H, J = 7.8, 4.8 Hz), 
4.38-4.31 (m, 2 H), 4.26 (q, 1 H, J = 6.9 Hz), 3.26-3.20 (m, 3 H), 1.65-1.59 (m, 2 H), 1.59-
1.52 (m, 2 H), 1.44-1.38 (m, 4 H)]. 
 
2-amino-3-oxo-3-((6-(4-sulfamoylbenzamido)hexyl)amino)propane-1-sulfonic acid (5) 
Compound 18 (22 mg, 33 μmol) was dissolved in 2 ml of a mixture piperidine/ACN 1:10 
and stirred at room temperature for 30 min. After solvent and piperidine evaporation, the 
solid was washed 3 times with portions of 4 ml of ACN. The solid was then dissolved in 2 
ml of DMSO, purified by preparative HPLC and lyophilized to give compound 5 (3 mg, 7 
μmol, 21%). [HRMS (ESI) calculated for C16H26N4NaO7S2+ [M+Na]+ 473.1135; found 
473.1138. 1H NMR (600 MHz, MeOD) ? 8.01-7.96 (m, 4 H), 4.21 (dd, 1 H, J = 3.4, 10.0 Hz), 
3.42 (t, 2 H, J = 7.1 Hz), 3.29-3.28 (m, 1 H), 3.27-3.26 (m, 2 H), 3.15 (dd, 1 H, J = 14.5, 
10.0 Hz), 1.69-1.65 (m, 2 H), 1.61-1.56 (m, 2 H), 1.44 (m, 2 H). 13C NMR (151 MHz, MeOD) 
? 167.4, 166.9, 146.3, 137.8, 127.5, 125.9, 50.5, 50.4, 39.5, 39.3, 28.9, 28.7, 26.2.]. 
6.2 Biology 
6.2.1 Cloning 
The vectors pET-51b(+) encoding for either SNAP-YPet-P15(GGS)2P15-CFP-HCA or SNAP-
CLIP were kindly provided by Dr. Rudolf Griss (Laboratory of Protein Engineering, EPFL); 
the pEBTet vector131 encoding for HDM2 was a kind gift from Dr. Grazvydas Lukinavicius 
(Laboratory of Protein Engineering, EPFL). DNA primers and oligos were provided by Mi-
crosynth. QIAquick Gel Extraction Kits, QIAprep Spin Miniprep Kits and Qiagen Plasmid 
Midi Kit were purchased from Qiagen. All the polymerase chain reactions (PCRs) were per-
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formed using KOD Hot Start Polymerase (Novagen). Restriction enzymes, antarctic phos-
phatase, ligases and polymerases were purchased from New England Biolabs (NEB) and 
Thermo Fischer.  
The assembly of vectors and PCR products was performed either by classical restriction/li-
gation techniques or using the Gibson Assembly132 Master Mix prepared in house. All the 
cloning steps were performed following the manufacturer protocols. 
6.2.1.1 Amino  acid sequence of  the HCA-based sensor 
MASWSHPQFEKGADDDDKVPMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAA
DAVEVPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLK
VVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGLAVKEW
LLAHEGHRLGKPGLGTSMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK
LLCTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNI
EDGGVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALFKDPNEKRDHMVLLEFLTAAGITEGM
NELYKEFPPPPPPPPPPPPPPPGGSGGSPPPPPPPPPPPPPPPGGRMVSKGEELFTGVVPILVEL
DGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTWGVQCFSRYPDHMKQ
HDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY
NYISHNVYITADKQKNGIKAHFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSAL
SKDPNEKRDHMVLLEFVTAATSAGGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDT
HTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHW
GSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQK
VVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVL
KFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFKRAPGFSSISAHHHHHHHHHH 
purple: Strep-tag II, His10-tag for protein purification 
red: SNAP-tag 
orange: YPet 
dark blue: polyproline-(GGS)2-polyproline linker 
light blue: CFP 
green: HCAII 
6.2.1.2 Amino  acid sequence of  the p53-based sensor 
MAWSHPQFEKGADDDDKVPSQETFSDLWKLLPENSTMSKGEELFTGVVPILVELDGDVNGH
KFSVSGEGEGDATYGKLTLKLLCTTGKLPVPWPTLVTTLGYGVQCFARYPDHMKQHDFFKSA
MPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV
YITADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALFKDPNE
KRDHMVLLEFLTAAGITEGMNELYKEFPPPPPPPPPPPPPPPGGSGGSPPPPPPPPPPPPPPPGG
RMVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLV
TTLTWGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRI
ELKGIDFKEDGNILGHKLEYNYISHNVYITADKQKNGIKAHFKIRHNIEDGSVQLADHYQQNTP
IGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAATSMCNTNMSVPTDGAVTTSQIPA
SEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGD
LFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRAPGFSSISAHHHHHHHHHH 
purple: Strep-tag II, His10-tag for protein purification 
red: p53 (15-29) fragment 
orange: YPet 
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dark blue: polyproline-(GGS)2-polyproline linker 
light blue: CFP 
green: HDM2 (1-125) fragment 
6.2.1.3 Amino  acid sequence of  the SNAP-CLIP 
MASWSHPQFEKGADDDDKVPHMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSA
ADAVEVPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLL
KVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGLAVKE
WLLAHEGHRLGKPGLGGRLEVLFQGPKAFLEMDKDCEMKRTTLDSPLGKLELSGCEQGLHK
IIFLGKGTSAADAVEVPAPAAVLGGPEPLIQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFT
RQVLWKLLKVVKFGEVISESHLAALVGNPAATAAVNTALDGNPVPILIPCHRVVQGDSDVGPYL
GGLAVKEWLLAHEGHRLGKPGLGGAPGFSSISAHHHHHHHHHH 
purple: Strep-tag II, His10-tag for protein purification 
red: SNAP-tag 
green: HDM2 (1-125) fragment 
6.2.2 Sensor expression and purification from HEK293 EBNA1 cells 
Phosphate buffered saline (PBS), FreeStyle 293 medium and PageRuler Prestained Protein 
Ladder 10-170KDa were purchased from Life Technologies. ExCell 293 medium, RPMI 
1640 medium with 0.1% pluronic F68 were purchased from SAFC Biosciences. Doxycy-
cline hydrochloride, polyethylenimine and CelLytic M were purchased from Sigma. EDTA-
free protease inhibitor cocktail tablets were purchased from Roche, Strep-Tactin Superflow 
columns were bought from IBA, Ni-NTA Agarose was purchased from Macherey-Nagel and 
centrifugal filters for protein concentration were purchased from Millipore. Cell incubators 
were set at 37°C, 5% v/v CO2, shaking speed 120 rpm, unless otherwise indicated. The 
concentration of protein solutions was measured with Nanodrop provided by Thermofisher. 
Suspention-adapted HEK293 EBNA1 cells were routinely maintained in serum-free ExCell 
293 medium with 4 mM glutamine. On the day before transfection, cells were inoculated 
into fresh medium at a density of 1·106 cells/ml. The next day, 1·109 cells were harvested 
by centrifugation (1200 rpm, 5 min) and resuspended at a density of 20·106 cells in 50 ml 
of RPMI 1640 medium prewarmed at 37°C and supplemented with 0.1% pluronic F-68. 
Then 1.5 mg of plasmid DNA and 3 mg, 1 mg/ml in H2O of linear polyethyleneimine were 
added and mixed. The cells were incubated under orbital shaking at 180 rpm. After 1 hour 
the transfected culture was transferred to a 5L glass bottle containing 950 ml of prewarmed 
FreeStyle 293 medium with 4 mM glutamine. The culture was transferred to an incubator 
shaker with agitation at 120 rpm for one day. After this time, doxycycline 1 μg/ml was 
added for expression enhancement, and the cells were incubated for 4 more days. 
The cells were then pelleted (800 rpm, 5 min) and washed three times with 100 ml of PBS. 
The cell pellet was then resuspended in 40 ml of CelLytic M precooled to 4°C and supple-
mented with EDTA-free protease inhibitor cocktail and imidazole 5 mM. The solution was 
incubated at 4°C for 20 min with mild shaking; the cells debris were harvested by centrif-
ugation, and the sensor protein contained in the supernatant was purified using a Ni-NTA 
column followed by a Strep-Tactin column according the suppliers’ instructions. The re-
sulting protein solution was concentrated on a centrifugal filter 50 KDa cutoff and the 
protein concentration was calculated based on the extinction coefficient of YPet (?517 = 
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104000). The protein was stocked in 50% glycerol at -20°C and its mass was checked by 
electrophoresis. 
6.2.3 Determination of the HCA sensor labeling kinetics in vitro 
Bovine serum albumin (BSA) heat shock fraction was purchased from Sigma; SNAP-Cell 
TMR-Star was purchased from New England Biolabs (NEB). 
A solution of the HCA-based sensor 1 μM and substrate of interest 4 μM in 50 mM HEPES 
pH=7.2, 50 mM NaCl, BSA 0.5 mg/ml was prepared. At different time points an aliquot of 
the sensor solution was mixed 1:2 with a solution of TMR-Star 50 μM freshly prepared. An 
aliquot of sensor without any substrate was also prepared and mixed in the same way with 
TMR-Star. The aliquots were then loaded on a gel for electrophoresis and for each band 
the fluorescence in the TMR channel was quantified and inversely related to the degree of 
the sensor labelling with the substrate of interest. The quantification of the TMR-fluores-
cence intensity was performed using the software ImageJ: the integrated intensity of the 
rectangular selection around each band was compared to the one of the unlabelled sensor 
aliquot (0% labelling). Therefore, the higher the labelling degree, the weaker the TMR-flu-
orescence intensity of the band. The final results summarized in Figure 3:6 are presented 
as average of three independent measurements followed by standard deviation. 
6.2.4 Titration of analytes in vitro 
Black, non-binding, flat bottom 96-well plates were purchased from Greiner Bio-One, cen-
trifugal filters Amicon Ultra were purchased from Millipore. Fluorescence measurements 
were performed using an Infinite M1000 spectrofluorometer Tecan. 
The labelling HCA-based sensor was performed by adding it 1 μM to a solution of BG or 
CP substrates 4 μM in 50 mM HEPES pH=7.2, 50 mM NaCl, 0.5 mg/ml BSA; the mixture 
was then incubated for 1 hour at room temperature. The p53-based sensor did not require 
labelling. The inhibitors of the p53-HDM2 interaction were provided by the industrial part-
ner Dr. T. Vorherr (Director Peptide Discovery, Novartis Institute of BioMedical Research) 
as lyophilized and salt-free powders, which were dissolved and stored as DMSO solutions. 
The concentration of the small molecules was calculated based on weight, the one of the 
peptides based on Trp and Tyr absorbance at 280 nm (?280(Trp) = 5690 M-1cm-1, ?280(Tyr) = 
1280 M-1cm-1)133. 
. In a 96-well plate the sensor protein was diluted down to 50 nM with 50 mM HEPES 
pH=7.2, 50 mM NaCl, 0.5 mg/ml BSA, 0.7% DMSO containing defined concentrations of 
analytes; for all analytes, in the well corresponding to the lowest concentration just pure 
DMSO was added. The solutions were incubated at room temperature for 1 hour before 
the fluorescence measurement. The excitation was carried out at 434 nm with a bandwidth 
of 15 nm and the spectra were recorded from 460 to 600 nm using a step size of 1 nm and 
bandwidth of 15 nm. 
In accordance with the design principles, increasing concentrations of analytes resulted in 
a reduction of the emission intensity of YPet (527 nm) and in a growth of the emission 
intensity of CFP (476 nm). The values of C50 were determined by plotting the ratio of CFP 
emission (476 nm, bandwidth 3 nm) over YPet emission (527 nm, bandwidth 3 nm) against 
the analyte concentration and by fitting the data with a single-site binding isotherm as 
previously described44:  
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? ? ????? ?
???? ? ?????
? ? ????????????
 
????? represents the ratio in absence of analyte and ???? represents the one at saturating 
concentration of analyte. The ratio change is defined as the ratio ???? /????? or, if expressed 
in percent, 100 ? (???? ? ?????)/?????. In the case of the titrations of 1CFY and sMTide CIS 
with the p53-based sensor the fitting was performed with the following binding isotherm 
containing the Hill's coefficient (n): 
? ? ????? ?
???? ? ?????
? ? ? ??????????????
 
The ????value corresponds to the concentration of analyte at which the half maximal ratio 
change is reached. It should be noted that the ??? does not necessarily correspond to the 
???????? , concentration at which the sensor molecules are half in the open and half in the 
closed state: this condition is reached when each single channel separately gets to 50 % of 
the maximum change. The values of ???????? were obtained by fitting the intensity ratio data 
with the following binding isotherm54, 79: 
? ? ??????????????? ? ?????????
???????
???????????????? ? ?????????????????
 
where ?????? and ?????? represent the intensities at the CFP emission respectively of the 
analyte-bound and unbound sensor, ??????? and ??????? represent the intensities at the YPet 
emission respectively of the analyte-bound and unbound sensor, ????????? is the concen-
tration of the corresponding analyte and ???????? is the dissociation constant. The fitting for 
the calculation of ???????? of 1CFY and sMTide CIS was modified to contain the Hill's coeffi-
cient: 
? ? ???????????????
? ? ?????????????????
????????????????? ? ??????????????????
 
The fluorescence intensities at the CFP and YPet emissions of the bound and unbound 
sensor were calculated by fitting the curves of intensity against concentration of analyte 
with the following isotherm: 
? ? ??
?? ? ??
? ? ??
?
?????????
 
where ? is the emission intensity of either the donor or the acceptor, ?? and ?? are the 
respective emission intensities for the analyte-bound and unbound sensor, ????????? is the 
concentration of analyte. In the case of the intensity curves obtained with 1CFY and 
sMTide CIS, the fitting was modified as follows: 
? ? ??
?? ? ??
? ? ? ??
?
???????????
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The final results are presented as average of three independent measurements followed by 
standard deviation. 
6.2.5 Determination of the sensor's opening kinetic in vitro 
Fluorescence measurements were performed using an Infinite M1000 spectrofluorometer 
Tecan, which is equipped with an automatic injector. All kinetic experiments were per-
formed at 37°C, unless otherwise indicated. 
The protein sensor was diluted to 100 nM in 50 mM HEPES pH=7.2, 50 mM NaCl, 0.5 
mg/ml BSA and mixed 1:2 with a solution of analyte of interest at time zero. An orbital-
type mixing step of 3 seconds was introduced before the recording of the fluorescence 
emission intensities, in order to guarantee a good degree of homogeneity in the sensor-
analyte solution. The excitation was carried out at 434 nm and the fluorescence emissions 
of CFP (476 ± 3 nm) and YPet (527 ± 3 nm) were recorded over time.  
In accordance with the design principles, with the progressive binding of the analyte to the 
sensor resulted in a reduction of the emission intensity of YPet and in a growth of the 
emission intensity of CFP. The values of the sensor half-life of opening t1/2 were determined 
by plotting the ratio of CFP emission over YPet emission against time and by fitting the 
data with a mono- (for the HCA-based sensor) or a bi-exponential (for the p53-based sen-
sor) function: 
????? ? ???? ? ?????? ? ???????
??
???? 
????? ? ???? ? ?????? ? ???????
??
????? ? ???
??
?????  
????? represents the ratio at time zero, ???? represents the ratio at saturation of the sensor. 
The value of the opening rate constant can be calculated from the value of t1/2: 
? ? ??????? 
The final results summarized in Table 3:2 are presented as average of three (in the case of 
the HCA-based sensor) or two (in the case of the p53-based sensor) independent measure-
ments followed by standard deviation. 
6.2.6 Semi stable adherent cell line generation 
Dubelcco’s modified eagle medium (DMEM), fetal bovine serum (FBS), Hank’s buffered salt 
solution (HBSS), GlutaMAX, trypsin-EDTA (0.05%) and puromycin dihydrochloride were 
purchased from Thermo Fisher. Tissue culture flasks were purchased from TPP and 
Lipofectamine 2000 by Invitrogen. Unless otherwise indicated, all cell lines were cultured 
in DMEM high glucose medium supplemented with 10% FBS and GlutaMAX; all semi-
stable cell lines were cultured in DMEM high glucose medium supplemented with 10% 
FBS, GlutaMAX and puromycin at different concentrations depending on the cell type. 
U2OS or HEK 293T cells were cultured on tissue culture flasks and splitted twice a week. 
The cells were transfected with pEBTet vectors using lipofectamine according to the pro-
vider's instructions. Starting from 24 hours after transfection the cells were cultured in 
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DMEM high glucose medium supplemented with 10% FBS and GlutaMAX and puromycin 
1 or 3 μg/ml respectively for U2OS and HEK 293T cells. 
6.2.7 Determination of the cell permeability of SNAP-tag substrates 
The CLIP-tag substrate BC-SiR was a kind gift of Dr. Luc Reymond (Laboratory of Protein 
Engineering, EPFL).  
The U2OS semi-stable cell line expressing the protein SNAP-CLIP was seeded in 6-well 
cultured plates in presence of doxycycline 1 μg/ml. 24 hours later the cells were labelled 
by exchanging the medium with fresh one containing doxycycline 1 μg/ml  and, per well, 
a different substrate 5 μM. One well was left in the old medium, without labelling; in an-
other the cells were labelled with SNAP-Cell Block, a non-fluorescent substrate that blocks 
the SNAP's active site. The cells were then incubated overnight. The following day the me-
dium was substituted with fresh one containing TMR-Star 5 μM. The cells were incubated 
for 30 min, washed 3 times with HBSS, incubated for 20 min at 4°C with CelLytic supple-
mented with protease inhibitor cocktail and BC-SiR 5 μM. Aliquots of the lysate of each 
well were loaded in an electrophoresis gel. For each band the fluorescence in the TMR 
channel was quantified, normalized for the fluorescence in the SiR channel (normalization 
for the protein concentration in each lysate) and inversely related to the degree of the sen-
sor labelling with the different substrates. The quantification of the TMR-fluorescence in-
tensity was performed using the software ImageJ. The integrated intensity of the rectan-
gular selection around each band in the TMR-channel was normalized by the the one in 
the SiR-channel. The normalized values were then compared to the ones of the cells la-
belled with just TMR-Star (0% labelling) and SNAP-Cell Block (100% labelling): the higher 
the labelling degree, the weaker the TMR-fluorescence intensity of the band. The final re-
sults summarized in Figure 3:5 are presented as average of three independent measure-
ments followed by standard deviation. 
6.3 Microscopy 
6.3.1 General information 
Wide-field microscopy experiment were carried out with IN Cell Analyser 2200 from GE 
equipped with: a Nikon 20X objective, NA 0.75, Plan Apo, CFI/60; CFP excitation (438 nm, 
bandwidth 24 nm) and emission (475 nm, bandwidth 24 nm) filter and YFP emission filter 
(548 nm, bandwidth 22 nm) on QUAD 3 Polychroic mirror; plate and lid heater, CO2 cham-
ber. For each frame, two fluorescence emission images (CFP and FRET) were recorded 
consecutively with exposure time 100 ms, Binning 4X4, Laser Autofocus power level 10%, 
refocus at each time point during time-course experiments. All live cell imaging experi-
ments were performed at 37°C, 5% v/v CO2. Tissue culture treated 96-well plate, black, 
flat bottom with lid were purchased from Corning. 
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Figure 6:1 Example of microscopy image (YPet emission) of the U2OS cell line expressing the HCA-based sen-
sor. 
After recording, the images were analysed with the software Cell Profiler 2.1.1. The Analysis 
Modules list consisted in:  
1. ImageMath, to sum CFP and FRET images;  
2. Morph, to perform the operation Tophat with the structuring element Octagon;  
3. IdentifyPrimaryObjects, to identify cells with A Global Threshold strategy, Back-
ground Thresholding Method;  
 
 
Figure 6:2 Outline of the cells identified after the first image manipulation modules. 
 
4. ExpandOrShrinkObjects, to expand cells of 5 pixels; 
 
 
Figure 6:3 Outline of the 5 pixels-expanded cells. 
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5. IdentifySecondaryObjects, to identify as an object the region between the image bor-
ders and the cells identified in Module 3 expanded of 15 pixels; 
 
 
Figure 6:4 Outline of the 15 pixels-expanded cells. 
6. IdentifyTertiaryObjects, to identify the background region as the difference between 
the image resulting from Module 5 and the expanded cells identified in Module 4; 
 
 
Figure 6:5 Outline of the regions included between the 15 pixels and the 5 pixels-expanded cells. 
 
7. RelateObjects, to relate each cell to its specific background; 
8. TrackObjects, to track cells with an Overlap method; 
 
 
Figure 6:6 Assignment of an ID number to each cell. 
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9. MeasureObjectIntensity, to measure in the CFP and FRET images the average inten-
sity of the regions identified in Module 3 and 6 (respectively cells and background); 
10. ExportToSpreadsheet, to export the results of the measurement in an Excel file. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:7 (A) Overlay of the outlines of the cells (green), the 5 pixels-expanded cells (red) and the 15 pixels-
expanded cells (blue). As background, the region included between the red and the blue line was used. (B) 
Output table summarizing the average intensity values per cell and per time. (C) Output table of the mathe-
matical analysis of the data collected in (B). 
 
CFP and FRET intensity means and standard deviations of the mean for the cells treated 
in the same conditions were calculated and used for intensity ratio plots. The average 
number of cells per condition was above 100. 
6.3.2 Titration of analytes in cellulo 
The semi-stable U2OS cell line expressing a protein sensor was seeded in a 96-well plate 
in presence of doxycycline 1 μg/ml. If needed (for the HCA-based sensor), 24 hours later 
the cells were labelled by exchanging the medium with fresh one containing the substrate 
5 μM and doxycycline 1 μg/ml. One day later the cells were washed 3 times with HBSS 
and incubated for 30 min after the last washing step. Then the cells were incubated with 
different dilutions of analytes in HBSS, 0.7% DMSO for 1 or 2 hours (the latter incubation 
time was used for peptides who have slower cellular uptake) and imaged. The final results 
are presented as average of two (for the p53-based sensor) or three (for the HCA-based 
sensor) independent measurements followed by standard deviation of the mean; at least 
100 cells were tested per condition. 
A B
C
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6.3.3 Cell entry and washout kinetics in cellulo 
The semi-stable U2OS cell line expressing a protein sensor was seeded in a 96-well plate 
in presence of doxycycline 1 μg/ml. If needed (for the HCA-based sensor), 24 hours later 
the cells were labelled by exchanging the medium with fresh one containing the substrate 
5 μM and doxycycline 1 μg/ml. One day later the cells were washed 3 times with HBSS 
and incubated for 30 min after the last washing step. The supernatant was then manually 
exchanged with a solution of analyte in HBSS, 0.7% DMSO and the time-course imaging 
was started, with a delay of 15 seconds between the addition of analyte and the first rec-
orded frame. For washout experiments, the analyte solution over the cells was manually 
exchanged with fresh HBSS and the time-course imaging was restarted. The opening half-
life values were calculated as average of two (for the p53-based sensor) or three (for the 
HCA-based sensor) independent measurements followed by standard deviation of the 
mean; at least 100 cells were tested per condition. 
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